<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anticoagulants for acute ischaemic stroke - Wang, X - 2021 | Cochrane Library</title> <meta content="Anticoagulants for acute ischaemic stroke - Wang, X - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000024.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anticoagulants for acute ischaemic stroke - Wang, X - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000024.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000024.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Anticoagulants for acute ischaemic stroke" name="citation_title"/> <meta content="Xia Wang" name="citation_author"/> <meta content="University of New South Wales" name="citation_author_institution"/> <meta content="Menglu Ouyang" name="citation_author"/> <meta content="University of New South Wales" name="citation_author_institution"/> <meta content="Jie Yang" name="citation_author"/> <meta content="Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China" name="citation_author_institution"/> <meta content="yangjie1126@163.com" name="citation_author_email"/> <meta content="Lili Song" name="citation_author"/> <meta content="The George Institute China at Peking University Health Science Center" name="citation_author_institution"/> <meta content="Min Yang" name="citation_author"/> <meta content="The First Affiliated Hospital of Chengdu Medical College" name="citation_author_institution"/> <meta content="Craig S Anderson" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD000024.pub5" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/10/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000024.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000024.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000024.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Activities of Daily Living; Anticoagulants [adverse effects]; *Brain Ischemia [drug therapy]; Heparin [adverse effects]; *Ischemic Stroke; *Stroke [drug therapy, prevention &amp; control]; Systematic Reviews as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000024.pub5&amp;doi=10.1002/14651858.CD000024.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="afU96cMv";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000024\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000024\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ko","pt","ms","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000024.pub5",title:"Anticoagulants for acute ischaemic stroke",firstPublishedDate:"Oct 22, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000024.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000024.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000024.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000024.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000024.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000024.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000024.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000024.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000024.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000024.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>14780 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000024.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-sec-0078"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-sec-0068"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/appendices#CD000024-sec-0084"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/table_n/CD000024StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/table_n/CD000024StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anticoagulants for acute ischaemic stroke</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information#CD000024-cr-0004">Xia Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information#CD000024-cr-0005">Menglu Ouyang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information#CD000024-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Jie Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information#CD000024-cr-0007">Lili Song</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information#CD000024-cr-0008">Min Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information#CD000024-cr-0009">Craig S Anderson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information/en#CD000024-sec-0097">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 October 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000024.pub5">https://doi.org/10.1002/14651858.CD000024.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000024-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000024-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000024-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000024-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000024-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000024-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD000024-abs-0007">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000024-abs-0001" lang="en"> <section id="CD000024-sec-0001"> <h3 class="title" id="CD000024-sec-0001">Background</h3> <p>Stroke is the third leading cause of early death worldwide. Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Patient outcomes might be improved if they are offered anticoagulants that reduce their risk of developing new blood clots and do not increase the risk of bleeding. This is an update of a Cochrane Review first published in 1995, with updates in 2004, 2008, and 2015. </p> </section> <section id="CD000024-sec-0002"> <h3 class="title" id="CD000024-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of early anticoagulation (within the first 14 days of onset) for people with acute presumed or confirmed ischaemic stroke. </p> <p>Our hypotheses were that, compared with a policy of avoiding their use, early anticoagulation would be associated with: </p> <p>• reduced risk of death or dependence in activities of daily living a few months after stroke onset; </p> <p>• reduced risk of early recurrent ischaemic stroke;</p> <p>• increased risk of symptomatic intracranial and extracranial haemorrhage; and</p> <p>• reduced risk of deep vein thrombosis and pulmonary embolism.</p> </section> <section id="CD000024-sec-0003"> <h3 class="title" id="CD000024-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register (August 2021); the Cochrane Database of Systematic Reviews (CDSR); the Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 7), in the Cochrane Library (searched 5 August 2021); MEDLINE (2014 to 5 August 2021); and Embase (2014 to 5 August 2021). In addition, we searched ongoing trials registries and reference lists of relevant papers. For previous versions of this review, we searched the register of the Antithrombotic Trialists' (ATT) Collaboration, consulted MedStrategy (1995), and contacted relevant drug companies. </p> </section> <section id="CD000024-sec-0004"> <h3 class="title" id="CD000024-sec-0004">Selection criteria</h3> <p>Randomised trials comparing early anticoagulant therapy (started within two weeks of stroke onset) with control in people with acute presumed or confirmed ischaemic stroke. </p> </section> <section id="CD000024-sec-0005"> <h3 class="title" id="CD000024-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials for inclusion, assessed trial quality, and extracted data. We assessed the overall certainty of the evidence for each outcome using RoB1 and GRADE methods. </p> </section> <section id="CD000024-sec-0006"> <h3 class="title" id="CD000024-sec-0006">Main results</h3> <p>We included 28 trials involving 24,025 participants. Quality of the trials varied considerably. We considered some studies to be at unclear or high risk of selection, performance, detection, attrition, or reporting bias. Anticoagulants tested were standard unfractionated heparin, low‐molecular‐weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors. Over 90% of the evidence is related to effects of anticoagulant therapy initiated within the first 48 hours of onset. No evidence suggests that early anticoagulation reduced the odds of death or dependence at the end of follow‐up (odds ratio (OR) 0.98, 95% confidence interval (CI) 0.92 to 1.03; 12 RCTs, 22,428 participants; high‐certainty evidence). Similarly, we found no evidence suggesting that anticoagulant therapy started within the first 14 days of stroke onset reduced the odds of death from all causes (OR 0.99, 95% CI 0.90 to 1.09; 22 RCTs, 22,602 participants; low‐certainty evidence) during the treatment period. Although early anticoagulant therapy was associated with fewer recurrent ischaemic strokes (OR 0.75, 95% CI 0.65 to 0.88; 12 RCTs, 21,665 participants; moderate‐certainty evidence), it was also associated with an increase in symptomatic intracranial haemorrhage (OR 2.47; 95% CI 1.90 to 3.21; 20 RCTs, 23,221 participants; moderate‐certainty evidence). Similarly, early anticoagulation reduced the frequency of symptomatic pulmonary emboli (OR 0.60, 95% CI 0.44 to 0.81; 14 RCTs, 22,544 participants; high‐certainty evidence), but this benefit was offset by an increase in extracranial haemorrhage (OR 2.99, 95% CI 2.24 to 3.99; 18 RCTs, 22,255 participants; moderate‐certainty evidence). </p> </section> <section id="CD000024-sec-0007"> <h3 class="title" id="CD000024-sec-0007">Authors' conclusions</h3> <p>Since the last version of this review, four new relevant studies have been published, and conclusions remain consistent. People who have early anticoagulant therapy after acute ischaemic stroke do not demonstrate any net short‐ or long‐term benefit. Treatment with anticoagulants reduced recurrent stroke, deep vein thrombosis, and pulmonary embolism but increased bleeding risk. Data do not support the routine use of any of the currently available anticoagulants for acute ischaemic stroke. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000024-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000024-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000024-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000024-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000024-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000024-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000024-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD000024-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000024-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD000024-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000024-abs-0002" lang="en"> <h3>Early treatment with blood‐thinning drugs for people who have had a stroke</h3> <p><b>Review question</b><br/>We wanted to know whether people treated with anticoagulants (blood‐thinning drugs) soon after having a stroke got better or not, and whether they had problems with bleeding. </p> <p><b>Background</b><br/>Millions of people around the world have a stroke every year. Most strokes take place when a blood clot blocks a blood vessel leading to the brain. When the blood supply to the brain is restricted or blocked, brain cells begin to die. This can lead to brain injury, which can be permanent, causing disability and possibly death. Damage from a stroke can cause arm or leg weakness, or difficulties with language or vision. Strokes are sometimes fatal but more often leave survivors unable to do the things they used to do. Because strokes are common and cause such damage, researchers are looking at ways to get rid of the blood clot soon after the stroke happens. One way to do this is to use blood‐thinning drugs called anticoagulants. If patients respond well to anticoagulants, they might be able to avoid the bad effects of a stroke. The main problem with anticoagulants is that if they cause bleeding, the patient can have very serious outcomes from this. </p> <p><b>Search date</b><br/>The evidence is current to August 2021. </p> <p><b>Study characteristics</b><br/>To find the best answer, we looked for studies in which investigators compared any anticoagulant to another medicine, to a dummy medicine that does not contain any active ingredients (placebo), or to normal care. To make the comparison fair, all patients in these studies must have had the same random chance (like the flip of a coin) to receive the anticoagulant, the other treatment, or normal care. We included in this updated review 28 studies involving 24,025 people with stroke. Two studies enrolled participants within 12 hours of stroke onset, four within 24 hours, and 10 within 48 hours. </p> <p><b>Key results</b><br/>People treated with anticoagulants did not have less long‐term disability, and they experienced more bleeding. Anticoagulant‐treated patients had a lesser chance of developing blood clots in their legs and in their lungs following their stroke, but these benefits were offset by an increased number of bleeds. </p> <p><b>Certainty of the evidence</b><br/>We used standard methods to assess the certainty of the evidence. We rated our confidence in the evidence based on factors such as study methods, numbers of participants included in the studies, and consistency of findings across studies. Low‐certainty evidence means we are uncertain about the results. In the same way, high‐certainty evidence means we are very certain about the results of this review. </p> <p><b>Conclusion</b><br/>This review did not provide any evidence to suggest that early use of anticoagulants is beneficial overall for people with stroke caused by blood clots. More research is needed to find out if there are ways to select people with stroke who will benefit most from anticoagulants without suffering the bleeding complications. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000024-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000024-sec-0078"></div> <h3 class="title" id="CD000024-sec-0079">Implications for practice</h3> <section id="CD000024-sec-0079"> <p>Evidence from this systematic review indicates that, compared with control, the types of anticoagulants tested in people with acute ischaemic stroke have no effect in terms of death in the short term, or death or dependency after follow‐up of at least one month. A reduction in recurrent ischaemic stroke during the treatment period is exactly offset by an increase in intracranial haemorrhage. Although anticoagulants decrease deep vein thrombosis and pulmonary embolus, these benefits are once again offset by similarly sized increases in extracranial haemorrhage. </p> <p>Data do not support the routine use of early high‐dose intravenous or subcutaneous anticoagulants in any form for people with acute ischaemic stroke. Low‐dose subcutaneous regimens will prevent deep vein thrombosis, but with a small but definitely increased risk of major haemorrhage. Therefore, it may be advisable to consider safer alternatives for immobile patients (such as aspirin, pneumatic compression stockings, or early mobilisation). </p> <p>The data reviewed from trials comparing these agents with control do not support the use of low‐molecular‐weight heparins, heparinoids, or thrombin inhibitors for the treatment of acute ischaemic stroke. </p> <p>The analysis performed did not identify any category of patients who derived a clear net benefit. Clinicians who feel compelled to use early anticoagulants for specific categories of patients following acute ischaemic stroke should weigh any potential theoretical benefits versus the known risk of bleeding. Evidence of benefit and safety favors aspirin as an effective antithrombotic alternative to anticoagulation when used in the acute phase of ischaemic stroke. </p> </section> <h3 class="title" id="CD000024-sec-0080">Implications for research</h3> <section id="CD000024-sec-0080"> <p>This review has not provided reliable evidence on a number of important categories of patients with acute cerebrovascular disease who might plausibly derive net benefit from early anticoagulation (very recent transient ischaemic attacks (within hours or days of onset), crescendo transient ischaemic attacks, and progressing ischaemic stroke are a few examples), and further trials targeted at these groups (perhaps with new agents) may be warranted. The choice of comparator agent against which to test any anticoagulant will depend on a number of factors, but further trials comparing anticoagulants against control seem unlikely. </p> <p>Clinicians who wish to continue to use intensive intravenous dose‐adjusted heparin regimens routinely to treat specific categories of stroke patients should provide convincing evidence from new randomised controlled trials to support such practices. </p> <p>This review has not provided clear evidence about the optimum antithrombotic regimen for prevention of deep vein thrombosis and pulmonary embolism in stroke patients. Aspirin alone, low‐dose subcutaneous heparin, and use of an intermittent pneumatic compression device are all promising possibilities, but a very large‐scale randomised trial with several tens of thousands of participants would be required to determine which treatment (or which combination) offers the most favourable balance of risk and benefit for overall clinical outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000024-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000024-sec-0008"></div> <div class="table" id="CD000024-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Anticoagulant compared to control in acute presumed ischaemic stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anticoagulant compared to control in acute presumed ischaemic stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> acute presumed ischaemic stroke<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> anticoagulant<br/><b>Comparison:</b> control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with anticoagulant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dead or dependent at end of follow‐up (if &gt; 1 month)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>598 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>593 per 1000</b><br/>(578 to 605) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.98</b><br/>(0.92 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22428<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from all causes during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b><br/>(78 to 93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.99</b><br/>(0.90 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22602<br/>(22 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 3 studies included in this analysis had low risk in each domain; only 2 out of 22 studies enrolled more than 500 patients, clearly underpowered </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep vein thrombosis during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b><br/>(107 to 188) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.21</b><br/>(0.15 to 0.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>916<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies included in this analysis had low risk in each domain; all the studies were too underpowered to draw a firm conclusion; publication bias has been detected </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrent ischaemic or unknown stroke during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/>(24 to 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.75</b><br/>(0.65 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21665<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 2 studies included in this analysis had low risk in each domain</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic intracranial haemorrhage during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b><br/>(9 to 16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.47</b><br/>(1.90 to 3.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23221<br/>(21 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Publication bias has been detected</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic pulmonary embolism during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(4 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.60</b><br/>(0.44 to 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22544<br/>(14 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major extracranial haemorrhage during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(9 to 15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.99</b><br/>(2.24 to 3.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22255<br/>(18 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Publication bias has been detected</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423948318800395805" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423948318800395805</a>. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000024-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000024-sec-0009"></div> <section id="CD000024-sec-0010"> <h3 class="title" id="CD000024-sec-0010">Description of the condition</h3> <p>Stroke was the third leading cause of disability‐adjusted life‐years and early death among people of all ages worldwide in 2017 (<a href="./references#CD000024-bbs2-0157" title="KyuHH , AbateD , AbateKH , AbaySM , AbbafatiC , AbbasiN , et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet2018;392:1859–922. [PMID: 30415748]">Kyu‐2018</a>). Due to demographic (aging population) and lifestyle changes, the global burden of stroke is increasing, with the greatest burden noted in low‐ and middle‐income countries (<a href="./references#CD000024-bbs2-0153" title="FeiginVL , ForouzanfarMH , KrishnamurthiR , MensahGA , ConnorM , BennettDA , et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet2014;383(9913):245-54.">Feigin 2014</a>). In Western societies, ischaemic stroke is the most frequent pathological subtype of stroke (~80%) and is usually caused by a blood clot blocking flow in an artery supplying parts of the brain (<a href="./references#CD000024-bbs2-0152" title="FeiginVL , LawesCM , BennettDA , Barker-ColloSL , ParagV . Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009 Feb 21;8:355-69. [PMID: 19233729]">Feigin 2009</a>). </p> </section> <section id="CD000024-sec-0011"> <h3 class="title" id="CD000024-sec-0011">Description of the intervention</h3> <p>Anticoagulants are agents that act on the coagulation cascade to reduce fibrin polymerisation and thrombus formation; they are distinct from thrombolytic and defibrinogenating agents. Agents included in this review include unfractionated heparin, low‐molecular‐weight heparins, heparinoids, oral vitamin K antagonists, and specific thrombin inhibitors. The control was an inactive intervention ‐ placebo or no treatment ‐ delivered along with standard interventions of the respective healthcare systems. </p> <p>Heparins are administered parenterally (intravenously or subcutaneously) and so have sufficiently rapid onset to be used in the acute phase of ischaemic stroke, whereas oral anticoagulants, such as vitamin K antagonists and direct thrombin inhibitors, have slower onset of effect and may be of less use. Unfractionated heparin, a sulphated polysaccharide, acts by binding to antithrombin to inhibit factor Xa and deactivate thrombin. Important side effects include thrombocytopenia and osteopenia. Low‐molecular‐weight heparins are depolymerised heparin fragments approximately one‐third the size of unfractionated heparin that act primarily to inhibit factor Xa. They have a longer half‐life, greater bioavailability, and more predictable anticoagulant effect than unfractionated heparin. Heparinoids are glycosaminoglycans whose components catalyse the effect of heparin co‐factor 2 to inhibit thrombin. All heparins ultimately prevent fibrin formation and subsequent thrombosis. </p> </section> <section id="CD000024-sec-0012"> <h3 class="title" id="CD000024-sec-0012">How the intervention might work</h3> <p>Theoretically, early use of anticoagulants, by reducing the propagation of a thrombus in an intracerebral artery, may decrease the volume of infarcted cerebral tissue and so decrease the neurological deficit and risks of disability and death. Additionally, anticoagulants might inhibit the formation of new arterial and venous thromboses and so reduce the risk of early recurrent thromboembolic stroke, deep vein thrombosis, and pulmonary embolism. However, these benefits could be offset by the possibility that anticoagulant therapy may increase the risk of intracranial and extracranial haemorrhage. </p> </section> <section id="CD000024-sec-0013"> <h3 class="title" id="CD000024-sec-0013">Why it is important to do this review</h3> <p>This is an update of a Cochrane Review first published in 1995, and most recently updated in 2020. We included all randomised trials of anticoagulants versus control for people with acute presumed or confirmed ischaemic stroke. The aim is to establish the balance of risk and benefit of early anticoagulation for acute ischaemic stroke. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000024-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000024-sec-0014"></div> <p>To assess the effectiveness and safety of early anticoagulation (within the first 14 days of onset) for people with acute presumed or confirmed ischaemic stroke. </p> <p>Our hypotheses were that, compared with a policy of avoiding their use, early anticoagulation would be associated with: </p> <p> <ul id="CD000024-list-0001"> <li> <p>reduced risk of death or dependence in activities of daily living a few months after stroke onset; </p> </li> <li> <p>reduced risk of early recurrent ischaemic stroke;</p> </li> <li> <p>increased risk of symptomatic intracranial and extracranial haemorrhage; and</p> </li> <li> <p>reduced risk of deep vein thrombosis and pulmonary embolism.</p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000024-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000024-sec-0015"></div> <section id="CD000024-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000024-sec-0017"> <h4 class="title">Types of studies</h4> <p>We sought all unconfounded, truly randomised trials in which early treatment with anticoagulants was compared with control for people with acute presumed or confirmed ischaemic stroke. People with ischaemic stroke due to cerebral venous thrombosis were not specifically included in these trials, and so are not represented in this review. People with transient ischaemic attacks (TIAs) also are not included in this review. We did not include trials in which allocation to treatment or control group was not truly random, or in which allocation was not adequately concealed (e.g. allocation by alternation, date of birth, hospital number, day of the week, open random number list), because foreknowledge of treatment allocation could lead to biased treatment allocation, leading to overestimation of the treatment effect by up to 30% (<a href="./references#CD000024-bbs2-0161" title="Odgaard-JensenJ , VistGE , TimmerA , KunzR , AklEA , SchünemannH , et al. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews2011, Issue Issue 4. Art. No: MR000012. [DOI: 10.1002/14651858.MR000012.pub3]">Odgaard‐Jensen 2011</a>). We included trials in which it is unclear whether the method of randomisation provided adequate concealment of allocation. </p> </section> <section id="CD000024-sec-0018"> <h4 class="title">Types of participants</h4> <p>This review was confined to early treatment of acute ischaemic stroke; therefore we excluded the following types of trials: those that randomised participants more than 14 days after stroke onset, those that included only people with TIAs, and those that included only people with intracerebral haemorrhage, confirmed by appropriate brain imaging before entry. We included trials in which the pathological type of stroke was not confirmed by scanning before entry, as a majority of such strokes are ischaemic (<a href="./references#CD000024-bbs2-0144" title="BamfordJ , SandercockP , DennisM , BurnJ , WarlowC . A prospective study of acute cerebrovascular disease in the community: The Oxfordshire Community Stroke Project 1981-1986. 2. Incidence, case fatality and overall outcome at one year of cerebral infarction, primary intracerebral haemorrhage and subarachnoid haemorrhage. Journal of Neurology, Neurosurgery and Psychiatry1990;53:16-22.">Bamford 1990</a>). </p> </section> <section id="CD000024-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Anticoagulants are broadly defined as agents that act on the coagulation cascade to exert an anticoagulant effect, excluding thrombolytic agents (such as alteplase ) and defibrinogenating agents (such as ancrod). Use of thrombolytic agents for acute ischaemic stroke is the topic of a separate Cochrane Review (<a href="./references#CD000024-bbs2-0166" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD000213. [DOI: 10.1002/14651858.CD000213]">Wardlaw 2014</a>), as is use of fibrinogen‐depleting agents (<a href="./references#CD000024-bbs2-0155" title="HaoZ , LiuM , CounsellC , WardlawJM , LinS , ZhaoX . Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD000091. [DOI: 10.1002/14651858.CD000091]">Hao 2012</a>). We included the following anticoagulants in this review: subcutaneous and intravenous standard unfractionated heparin, low‐molecular‐weight heparins, subcutaneous and intravenous heparinoids, oral vitamin K antagonists, factor Xa inhibitors, and specific thrombin inhibitors. </p> </section> <section id="CD000024-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>For each trial, we identified the number of participants originally randomly allocated to each treatment and control group. For both groups, we sought outcome information regarding the numbers of participants who met the following outcomes. </p> <section id="CD000024-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD000024-list-0002"> <li> <p>Death or dependency (i.e. people who were dead or were dependent on help from other people for their activities of daily living), at least one month after stroke. This minimum interval was used to allow time for recovery from the initial stroke. Comparable definitions of dependency were used in all of the trials assessed in this review </p> </li> </ul> </p> </section> <section id="CD000024-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD000024-list-0003"> <li> <p>Participants who died from any cause during the scheduled treatment period (generally shorter than the scheduled follow‐up period) </p> </li> <li> <p>Participants who died from any cause during the scheduled follow‐up period (greater than one month after stroke) </p> </li> <li> <p>Participants with objective evidence of deep vein thrombosis detected by the systematic use of imaging techniques such as iodine 125 fibrinogen scanning (I‐125 scan), ultrasound of the leg, plethysmography, or X‐ray contrast venography during the scheduled treatment period and during scheduled follow‐up. These methods detected clinically silent deep vein thrombosis while confirming or refuting the diagnosis for participants with clinical features suggestive of deep vein thrombosis. The outcome was therefore 'symptomatic or asymptomatic deep vein thrombosis'. Screening of participants by clinical observation alone was not considered adequate </p> </li> <li> <p>Particpants with recurrent stroke during the treatment period and during follow‐up that was either definitively ischaemic (haemorrhage excluded by brain imaging or autopsy) or of unknown type (no brain imaging or autopsy performed) </p> </li> <li> <p>Participants with symptomatic intracranial (intracerebral or extracerebral) haemorrhage, including symptomatic haemorrhagic transformation of the cerebral infarct, during the scheduled treatment period and during follow‐up. Haemorrhage must have been confirmed by appropriate brain imaging after clinical deterioration, or by autopsy </p> </li> <li> <p>Participants with any recurrent stroke or symptomatic intracranial haemorrhage during the treatment period or during long‐term follow up (as previously defined) </p> </li> <li> <p>Participants with at least one confirmed symptomatic pulmonary embolus diagnosed during life or at autopsy (symptomatic or not) within the scheduled treatment period and during scheduled follow‐up </p> </li> <li> <p>Participants with any major extracranial haemorrhage during the scheduled treatment period. The definition of major haemorrhage was usually taken from the original article, but if none was given, major haemorrhage was defined as any fatal bleed, or bleeding severe enough to require transfusion or operation </p> </li> </ul> </p> <p>Although we sought trials that reported the primary outcome (dead or dependent at least one month after stroke), we also included data from trials that reported only data on our secondary outcomes. </p> </section> </section> </section> <section id="CD000024-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>See the 'Specialized register' section at the <a href="https://apps.ccbs.ed.ac.uk/csrg/entity/searchmethods.pdf" target="_blank">Cochrane Stroke Group</a> website. We searched for trials published in all languages and arranged translation of relevant papers published in languages other than English . </p> <section id="CD000024-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Stroke Group Trials Register (last searched April 2020) and the following bibliographic databases and trials registers. </p> <p> <ul id="CD000024-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 7), in the Cochrane Library (<a href="./appendices#CD000024-sec-0085">Appendix 1</a>). </p> </li> <li> <p>Cochrane Database of Systematic Reviews (CDSR; 2021, Issue 7), in the Cochrane Library (<a href="./appendices#CD000024-sec-0085">Appendix 1</a>). </p> </li> <li> <p>Database of Reviews of Effects (DARE; 2014, Issue 6), in the Cochrane Library (<a href="./appendices#CD000024-sec-0085">Appendix 1</a>). </p> </li> <li> <p>Health Technology Assessment Database (HTA; 2014, Issue 6), in the Cochrane Library (<a href="./appendices#CD000024-sec-0085">Appendix 1</a>). </p> </li> <li> <p>MEDLINE (Ovid; 2014 to August 2021) (<a href="./appendices#CD000024-sec-0086">Appendix 2</a>). </p> </li> <li> <p>Embase (Ovid; 2014 to 14 August 2021) (<a href="./appendices#CD000024-sec-0087">Appendix 3</a>). </p> </li> </ul> </p> <p>Using a comprehensive search strategy, the Cochrane Stroke Group Trials Search Co‐ordinator had already completed a retrospective search of MEDLINE and Embase for all stroke trials to January 2014 and added all relevant trials to the Cochrane Stroke Group Trials Register. To avoid duplication of effort, we have limited the search of these two databases from January 2014 onwards. </p> </section> <section id="CD000024-sec-0025"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD000024-list-0005"> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">https://clinicaltrials.gov</a>; searched 5 August 2021) (<a href="./appendices#CD000024-sec-0088">Appendix 4</a>) </p> </li> <li> <p>International Standard Randomized Controlled Trials Number (ISRCTN) Registry (<a href="http://www.isrctn.com/" target="_blank">http://www.isrctn.com/</a>; searched 5 August 2021) (<a href="./appendices#CD000024-sec-0088">Appendix 4</a>) </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched 5 August 2021) (<a href="./appendices#CD000024-sec-0088">Appendix 4</a>) </p> </li> <li> <p>We scanned the reference lists of all relevant papers</p> </li> <li> <p>For previous versions of this review:</p> <ul id="CD000024-list-0006"> <li> <p>we contacted the following anticoagulant manufacturers in an effort to identify unpublished trials (last contact 1999): Alfa Wasserman (parnaparin and dermatan sulphate), Kabi (dalteparin), Knoll (reviparin), Leo (tinzaparin), Mediolanum (dermatan sulphate), Mitsubishi Chemical (argatroban/MD‐805), Novo (tinzaparin), Organon (danaparoid), Rhone‐Poulenc Rorer (enoxaparin), Sandoz (Sandoz LMWH), and Sanofi Winthrop (nadroparin and CY 222); </p> </li> <li> <p>we consulted a comprehensive guide to pharmaceutical development in the field of stroke (MedStrategy 1995) but have not updated the search, as relevant trials contained within it are included in the Cochrane Stroke Group Trials Register; and </p> </li> <li> <p>in August 1998, we searched the trials register held by the Antithrombotic Trialists' (ATT) Collaboration, but this is no longer available and relevant trials from the register are now contained in the Cochrane Stroke Group Trials Register </p> </li> </ul> </li> </ul> </p> </section> </section> <section id="CD000024-sec-0026"> <h3 class="title" id="CD000024-sec-0026">Data collection and analysis</h3> <p>We followed standard Cochrane methodological procedures. For this update, Joshua Cheyne (Cochrane Stroke Group Information Specialist) performed the searches. XW and MO then independently screened all titles and abstracts of identified references and excluded obviously irrelevant studies. XW obtained full‐text articles of the remaining studies, and both XW and MO independently assessed these for inclusion or exclusion. We resolved any disagreements by discussion with LS, JY, and CA. </p> <section id="CD000024-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (PS and CC, for trials included in the first version of this review; PS and Gordon Gubitz for the proceeding two updates following the original review; Ayeesha Kamal and PS for the 2008 update; PS and EK for the 2015 update; XW and MO for this version) independently selected trials for inclusion in the review. We resolved disagreements through discussion. The same two review authors assessed the methodological quality of each trial. </p> </section> <section id="CD000024-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted and cross‐checked the data. We sought data on the number of participants with each outcome event, by allocated treatment group, irrespective of compliance, and whether or not participants were subsequently deemed ineligible or were otherwise excluded from treatment or follow‐up, to allow an intention‐to‐treat (ITT) analysis. We also sought data on use of brain imaging prior to randomisation, delay from stroke onset to trial entry, types of patients included, and types of anticoagulant regimens used. If any of the above data were not available in the publications, we sought further information by corresponding with the trialists. </p> </section> <section id="CD000024-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of each of the included trials using the following criteria of internal validity: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, adequate reporting and handling of missing outcome data, selective outcome reporting, and other risks of bias. We followed the guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000024-bbs2-0156" title="HigginsJT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. [COCHRANE: www.training.cochrane.org/handbook.]">Higgins 2011</a>). Two review authors (MO, XW) independently assessed risk of bias for the included studies using RoB1. We followed GRADE recommendations to determine the certainty of the evidence (<a href="./references#CD000024-bbs2-0154" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924.">Guyatt 2008</a>). This involved considering risk of bias together with inconsistency, indirectness, imprecision, and publication bias. Two review authors (MO, XW) completed this assessment. </p> </section> <section id="CD000024-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>Results reported in the text are odds ratios (ORs; i.e. ratios of the odds of an unfavourable outcome among treatment‐allocated participants to the corresponding odds amongst controls), which we calculated using the Peto fixed‐effect method (<a href="./references#CD000024-bbs2-0142" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">APT 1994</a>). We calculated the significance of any differences between ORs (in relation to subgroup analyses) by using a standard method (<a href="./references#CD000024-bbs2-0141" title="AltmanDG , MatthewsJNS . Interaction 1: heterogeneity of effects. BMJ1996;313:486.">Altman 1996</a>). When relevant, we expressed the absolute effects of treatment on each outcome as the number needed to treat to benefit (NNTB) (i.e. to avoid one bad outcome event). For events that are adverse (such as intracranial haemorrhage), this was calculated as the number needed to treat to harm (NNTH). To calculate NNTBs or NNTHs, we used the NNT calculator at <a href="https://www2.ccrb.cuhk.edu.hk/stat/confidence%20interval/CI%20for%20ratio.htm" target="_blank">https://www2.ccrb.cuhk.edu.hk/stat/confidence%20interval/CI%20for%20ratio.htm</a>. This applies the point estimate of relative effect and its 95% confidence interval (CI), then calculates NNTB or NNTH for a specified control event rate. </p> </section> <section id="CD000024-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>All included studies were trials in which individuals were randomised and follow‐up was generally provided to a prespecified and fixed time point; all analyses were by ITT where possible (see <a href="#CD000024-sec-0032">Dealing with missing data</a>). For outcomes for which more than one event could occur during follow‐up, such as non‐fatal recurrent stroke, we counted only the first event. </p> </section> <section id="CD000024-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>For some outcomes (such as deep vein thrombosis and any intracranial haemorrhage), ITT analyses were not possible because all participants did not have the relevant investigation performed to detect the event. For these analyses, we used the number of participants in each group who had the appropriate investigation as the denominator for the main analyses. However, if we found statistically significant results, we also analysed best‐ and worst‐case scenarios: the best‐case scenario (with regards to treatment) assumed that none of the participants excluded from the analysis in the treatment group had an adverse outcome, whilst all those excluded from the control group did, and vice versa for the worst‐case analysis. </p> </section> <section id="CD000024-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We identified and measured statistical and clinical heterogeneity as recommended in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000024-bbs2-0150" title="Deeks JJ, Higgins JT, Altman DG (editors). Chapter 10. Analysing data and undertaking meta-analyses. In: Higgins JT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2021</a>). We estimated heterogeneity between trial results using the I² statistic (<a href="./references#CD000024-bbs2-0150" title="Deeks JJ, Higgins JT, Altman DG (editors). Chapter 10. Analysing data and undertaking meta-analyses. In: Higgins JT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Deeks 2021</a>). We defined thresholds for interpreting heterogeneity (I²) as follows. </p> <p> <ul id="CD000024-list-0007"> <li> <p>0% to 30%: no heterogeneity.</p> </li> <li> <p>30% to 50%: moderate heterogeneity.</p> </li> <li> <p>50% to 80%: substantial heterogeneity.</p> </li> <li> <p>80% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>Evaluation of heterogeneity was not based on I² alone, as the importance of consistency depends on several factors, but rather included an overall evaluation of the data. We also considered the P value, noting that with P &lt; 0.05, there was likely to be heterogeneity. </p> </section> <section id="CD000024-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to minimise publication bias by using a comprehensive search strategy that included searching for unpublished studies and searching trials registers. We examined the funnel plot for any evidence of asymmetry for three outcomes. Analyses including the greatest numbers of trials (and hence with the greatest statistical power) examined effects of treatment on death during the treatment period, death from all causes at final follow‐up, and deep vein thrombosis. </p> </section> <section id="CD000024-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We used <a href="./references#CD000024-bbs2-0163" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a> for the analyses, in which we grouped together trials of each type of anticoagulant (e.g. unfractionated heparin, low‐molecular‐weight heparins, heparinoids, oral vitamin K antagonists, thrombin inhibitors) to assess whether there were any significant differences between classes of anticoagulant agents. It should be noted that this was an indirect rather than a direct randomised comparison. </p> <p>We also specified the following classification of anticoagulant dosing regimens.</p> <p> <ul id="CD000024-list-0008"> <li> <p>Low fixed‐dose anticoagulant ‐ a dose intended to be sufficient for prevention of deep vein thrombosis and pulmonary embolism. </p> </li> <li> <p>Medium fixed‐dose anticoagulant ‐ a dose intended to have effects on arterial circulation, but not enough to require monitoring. </p> </li> <li> <p>Adjusted‐dose anticoagulant ‐ a dose adjusted by blood testing or by body weight to meet a specific target. </p> </li> </ul> </p> </section> <section id="CD000024-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For this update, we performed subgroup analyses for the primary outcome by:</p> <p> <ul id="CD000024-list-0009"> <li> <p>type of anticoagulant agent used; and</p> </li> <li> <p>dose of anticoagulant used, applying the classification above.</p> </li> </ul> </p> </section> <section id="CD000024-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>For this update, we performed the following sensitivity analyses for the primary outcome, restricting analyses to: </p> <p> <ul id="CD000024-list-0010"> <li> <p>trials in which the method of randomisation ensured adequate concealment of treatment allocation; </p> </li> <li> <p>trials in which all participants were recruited within 48 hours of stroke onset; and</p> </li> <li> <p>trials except <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>, as this trial contained most of the data relevant to the review. </p> </li> </ul> </p> <p>In the previous version of this review, we performed numerous sensitivity analyses to investigate whether exclusion or inclusion of trials with particular characteristics would alter the overall conclusions. These characteristics included trials that had intracerebral haemorrhages excluded by neuroimaging prior to trial entry, time from stroke onset (less than 48 hours versus more than 48 hours) to randomisation, or concomitant unconfounded treatment with antiplatelet agents; trials in which stroke was of suspected cardioembolic origin versus non‐cardioembolic origin; and trials that evaluated different anticoagulant doses. These analyses were not informative, and we have excluded them from this updated review for brevity and clarity. For future updates of the review, we do not plan to repeat these analyses unless substantial new trial data have been added. </p> </section> <section id="CD000024-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used 'Summary of findings' tables to summarise the data comparing control and anticoagulation on (1) death or dependency at the end of follow‐up (if &gt; 1 month), (2) death from all causes during the treatment period, (3) deep vein thrombosis during the treatment period, (4) recurrent ischaemic or unknown stroke during the treatment period, (5) symptomatic intracranial haemorrhage during the treatment period, (6) symptomatic pulmonary embolism during the treatment period, and (7) major extracranial haemorrhage during the treatment period. We used GRADE methods to assess the overall certainty of evidence for each outcome (<a href="./references#CD000024-bbs2-0154" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924.">Guyatt 2008</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000024-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000024-sec-0039"></div> <section id="CD000024-sec-0040"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD000024-sec-0105" title="">Characteristics of ongoing studies</a> and <a href="./references#CD000024-sec-0104" title="">Characteristics of excluded studies</a>. </p> <section id="CD000024-sec-0041"> <h4 class="title">Results of the search</h4> <p>For this update, we searched the Cochrane Stroke Group Trials Register and performed additional new comprehensive searches of the Cochrane Library databases, MEDLINE, and Embase. After we removed duplicate records, we screened the titles and abstracts of 9508 records from these electronic bibliographic databases and obtained the full text of 90 studies, of which we excluded 86 studies, leaving four new trials for inclusion. The total number of included studies in this review is 28. See <a href="#CD000024-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD000024-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram for 2020 update." data-id="CD000024-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for 2020 update.</p> </div> </div> </div> <p>We identified six new ongoing trials from searches of trials registers (see <a href="./references#CD000024-sec-0105" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD000024-sec-0042"> <h4 class="title">Included studies</h4> <p>We included in this review 28 trials with a total of 24,025 participants. Summary details for these trials are given in the <a href="./references#CD000024-sec-0103" title="">Characteristics of included studies</a> table. Of the 28 included studies, two enrolled participants within 12 hours of stroke onset (<a href="./references#CD000024-bbs2-0001" title="LaMonteMP , NashML , WangDZ , WoolfendenAR , SchulzJ , HurstingMJ , et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1). Stroke2004;35:1677-82. ">ARGIS‐1 2004</a>; <a href="./references#CD000024-bbs2-0002" title="BarretoAD , FordGA , ShenL , PedrozaC , TysonJ , CaiC , et al. Randomized, multicenter trial of ARTSS-2 (Argatroban with Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke2017;48:1608-10. [PMID: 28507269]">ARTSS‐2 2017</a>), four enrolled participants within 24 hours of stroke onset (<a href="./references#CD000024-bbs2-0006" title="DluhaJ , SivakS , KurcaE , DusenkaR , KalmarovaK , KoprusakovaMT , et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke - pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia2016;160:543-8. [PMID: 27646496]">Dluha 2016</a>; <a href="./references#CD000024-bbs2-0011" title="HommelM , for the FISS-bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovascular Diseases1998;8 Suppl 4:19. ">FISS‐bis 1998</a>; <a href="./references#CD000024-bbs2-0023" title="SarmaGR , RoyAK . Nadroparin plus aspirin versus aspirin alone in the treatment of acute ischemic stroke. Neurology India2003;51:208-10. [PMID: 14571005]">Sarma 2003</a>; <a href="./references#CD000024-bbs2-0026" title="AdamsJHP . Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke1994;25:545. TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischaemic stroke. JAMA1998;279:1265-72. ">TOAST 1998</a>), 11 enrolled participants within 48 hours of stroke onset (<a href="./references#CD000024-bbs2-0003" title="CazzatoG , ZorzonM , MaseG , AntonuttoL , IonaLG . Mesoglycan in the treatment of acute cerebral infarction [Il mesoglicano nelle ischemie cerebrali acute a focolaio]. Rivista di Neurologia1989;59:121-6. ">Cazzato 1989</a>; <a href="./references#CD000024-bbs2-0004" title="HakimAM , FurlanAJ , HartRG . Immediate anticoagulation of embolic stroke: a randomized trial. The Cerebral Embolism Study Group. Stroke1983;14:668-76. HakimAM , Ryder-CookeA , MelansonD . Sequential computerized tomographic appearances of strokes. Stroke1983;14:893-7. ">CESG 1983</a>; <a href="./references#CD000024-bbs2-0007" title="DukeRJ , TurpieAGG , BlochRF , DerbyIR , KronbyMH , BayerNH . Clinical trial of low-dose heparin for the prevention of stroke progression. Circulation1980;Suppl III:21. DukeRJ , TurpieAGG , BlochRF , TrebilcockRG . Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke-in-evolution. In: ReivichM , HurtigHI , editors(s). Cerebrovascular Disease. New York: Raven Press, 1983:399-405. ">Duke 1983</a>; <a href="./references#CD000024-bbs2-0008" title="DukeRJ , BlochRF , TurpieAGG , TrebilcockRG , BayerN . Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Annals of Internal Medicine1986;105:825-8. DukeRJ , BlochRF , TurpieAGG . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:782. EastonJD , ShermanDG , HartRG . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:781. LoeligerEA . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:781-2. ">Duke 1986</a>; <a href="./references#CD000024-bbs2-0009" title="EliasA , MilandreL , LagrangeG , AillaudMF , AlonzoB , ToulemondeF , et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). Revue de Medecine Interne1990;11:95-8. ">Elias 1990</a>; <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>; <a href="./references#CD000024-bbs2-0013" title="KwiecinskiH , PniewskiJ , KaminskaA , SzylukB . A randomized trial of fraxiparine in acute ischaemic stroke. Cerebrovascular Diseases1995;5:234. ">Kwiecinski 1995</a>; <a href="./references#CD000024-bbs2-0014" title="LiuS , LiuP , WangP , ZhangF , Wang l, WangY , et al. Argatroban increased the basal vein drainage and improved outcomes in acute paraventricular ischemic stroke patients. Medical Science Monitor2020;26:e924593. ">Liu 2020</a>; <a href="./references#CD000024-bbs2-0016" title="McCarthyST , TurnerJJ , RobertsonD , HawkeyCJ , MaceyDJ . Low dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet1977;ii:800-1. ">McCarthy 1977</a>; <a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a>), and the rest enrolled participants within 14 days. The age of participants in the included studies ranged from 28 to 92 years. A significant proportion of participants were over 70 years old. For example, 61% of participants enrolled in <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a> were aged 70 or older. Most trials included slightly more men than women and excluded people thought to be at high risk of bleeding (e.g. clotting disorders, hepatic failure, renal failure). In addition, 13 trials excluded people with a significant degree of hypertension (generally diastolic pressure &gt; 120 mmHg or systolic pressure &gt; 180 mmHg), and 10 trials excluded comatose people. </p> <p>The scheduled period of anticoagulant treatment in included trials was one to two weeks in 24 trials, and one month in four trials. The anticoagulants used were (one trial used two types of anticoagulants (<a href="./references#CD000024-bbs2-0006" title="DluhaJ , SivakS , KurcaE , DusenkaR , KalmarovaK , KoprusakovaMT , et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke - pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia2016;160:543-8. [PMID: 27646496]">Dluha 2016</a>) and therefore was considered as two trials): </p> <p> <ul id="CD000024-list-0011"> <li> <p>standard unfractionated subcutaneous heparin (six trials);</p> </li> <li> <p>standard unfractionated intravenous heparin (three trials);</p> </li> <li> <p>low‐molecular‐weight heparins (10 trials: two dalteparin, four nadroparin, one tinzaparin, one fraxiparin, one parnaparin, and one CY 222); </p> </li> <li> <p>subcutaneous heparinoid (two trials: one danaparoid and one mesoglycan);</p> </li> <li> <p>intravenous heparinoid (one danaparoid trial);</p> </li> <li> <p>oral vitamin K antagonists (two trials); and</p> </li> <li> <p>thrombin inhibitors (five trials: two MD805 trials, three argatroban).</p> </li> </ul> </p> <p>In trials using oral vitamin K antagonists, heparin was given intravenously for the first few days to provide rapid anticoagulation (<a href="./references#CD000024-bbs2-0015" title="MarshallJ , ShawDA . Anticoagulant therapy in acute cerebrovascular accidents: a controlled trial. Lancet1960;1:995-8. MarshallJ , ShawDA . Anticoagulant therapy in cerebrovascular disease. In: Proceedings of the Royal Society of Medicine. 1960:547-9. ">Marshall 1960</a>; <a href="./references#CD000024-bbs2-0018" title="BakerRN , BrowardJA , FangHC , FisherCM , GrochSN , HeymanA , et al. Anticoagulant therapy in cerebral infarction. Report on co-operative study. Neurology1962;12:823-9. Miller FisherC . Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A national cooperative study, interim report. Neurology1961;11:119-31. ">NAT‐COOP 1962</a>). Five trials randomised between two doses of anticoagulant as well as control (<a href="./references#CD000024-bbs2-0002" title="BarretoAD , FordGA , ShenL , PedrozaC , TysonJ , CaiC , et al. Randomized, multicenter trial of ARTSS-2 (Argatroban with Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke2017;48:1608-10. [PMID: 28507269]">ARTSS‐2 2017</a>; <a href="./references#CD000024-bbs2-0006" title="DluhaJ , SivakS , KurcaE , DusenkaR , KalmarovaK , KoprusakovaMT , et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke - pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia2016;160:543-8. [PMID: 27646496]">Dluha 2016</a>; <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0011" title="HommelM , for the FISS-bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovascular Diseases1998;8 Suppl 4:19. ">FISS‐bis 1998</a>; <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>); for the main analyses in this review, we combined the two anticoagulant groups for these trials. </p> <p>Eighteen trials routinely performed a CT head scan for all patients to rule out haemorrhage before randomisation (<a href="./references#CD000024-bbs2-0001" title="LaMonteMP , NashML , WangDZ , WoolfendenAR , SchulzJ , HurstingMJ , et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1). Stroke2004;35:1677-82. ">ARGIS‐1 2004</a>; <a href="./references#CD000024-bbs2-0002" title="BarretoAD , FordGA , ShenL , PedrozaC , TysonJ , CaiC , et al. Randomized, multicenter trial of ARTSS-2 (Argatroban with Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke2017;48:1608-10. [PMID: 28507269]">ARTSS‐2 2017</a>; <a href="./references#CD000024-bbs2-0003" title="CazzatoG , ZorzonM , MaseG , AntonuttoL , IonaLG . Mesoglycan in the treatment of acute cerebral infarction [Il mesoglicano nelle ischemie cerebrali acute a focolaio]. Rivista di Neurologia1989;59:121-6. ">Cazzato 1989</a>; <a href="./references#CD000024-bbs2-0004" title="HakimAM , FurlanAJ , HartRG . Immediate anticoagulation of embolic stroke: a randomized trial. The Cerebral Embolism Study Group. Stroke1983;14:668-76. HakimAM , Ryder-CookeA , MelansonD . Sequential computerized tomographic appearances of strokes. Stroke1983;14:893-7. ">CESG 1983</a>; <a href="./references#CD000024-bbs2-0006" title="DluhaJ , SivakS , KurcaE , DusenkaR , KalmarovaK , KoprusakovaMT , et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke - pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia2016;160:543-8. [PMID: 27646496]">Dluha 2016</a>; <a href="./references#CD000024-bbs2-0008" title="DukeRJ , BlochRF , TurpieAGG , TrebilcockRG , BayerN . Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Annals of Internal Medicine1986;105:825-8. DukeRJ , BlochRF , TurpieAGG . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:782. EastonJD , ShermanDG , HartRG . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:781. LoeligerEA . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:781-2. ">Duke 1986</a>; <a href="./references#CD000024-bbs2-0009" title="EliasA , MilandreL , LagrangeG , AillaudMF , AlonzoB , ToulemondeF , et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). Revue de Medecine Interne1990;11:95-8. ">Elias 1990</a>; <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0011" title="HommelM , for the FISS-bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovascular Diseases1998;8 Suppl 4:19. ">FISS‐bis 1998</a>; <a href="./references#CD000024-bbs2-0013" title="KwiecinskiH , PniewskiJ , KaminskaA , SzylukB . A randomized trial of fraxiparine in acute ischaemic stroke. Cerebrovascular Diseases1995;5:234. ">Kwiecinski 1995</a>; <a href="./references#CD000024-bbs2-0019" title="DesmukhM , BisignaniM , LandauP , OrchardTJ . Deep vein thrombosis in rehabilitating stroke patients. Incidence, risk factors and prophylaxis. American Journal of Physical Medicine and Rehabilitation1991;70:313-6. PambiancoG , OrchardT , LandauP . Deep vein thrombosis: prevention in stroke patients during rehabilitation. Archives of Physical Medicine and Rehabilitation1995;76:324-30. ">Pambianco 1995</a>; <a href="./references#CD000024-bbs2-0021" title="PrinsMH , den OttolanderGJH , GelsemaR , vanWoerkomTCM , SingAK , HellerI . Deep venous thrombosis prophylaxis with a LMW heparin (KABI 2165) in stroke patients. Thrombosis and Haemostasis1987;58:117. PrinsMH , GelsemaR , SingAK , vanHeerdeLR , den OttolanderGJ . Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis1989;19:245-50. ">Prins 1989</a>; <a href="./references#CD000024-bbs2-0023" title="SarmaGR , RoyAK . Nadroparin plus aspirin versus aspirin alone in the treatment of acute ischemic stroke. Neurology India2003;51:208-10. [PMID: 14571005]">Sarma 2003</a>; <a href="./references#CD000024-bbs2-0022" title="SandsetPM , DahlT , AbildgaardU . Venous thromboembolic complications in acute thrombotic stroke. Progress report from a randomized trial. Acta Neurologia Scandinavica1987;76:392. SandsetPM , DahlT , StirisM , RostadB , ScheelB , AbildgaardU . A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Seminars in Thrombosis and Hemostasis1990;16 Suppl:25-33. ">Sandset 1990</a>; <a href="./references#CD000024-bbs2-0024" title="TazakiY , KobayashiS , TogiH , OhtomoE , GotoF , ArakiG , et al. Therapeutic effect of thrombin inhibitor MD-805 in acute phase of cerebral thrombosis - Phase II double-blinded clinical trial (English translation). Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine)1986;63:3047-57. ">Tazaki 1986</a>; <a href="./references#CD000024-bbs2-0025" title="TazakiY , KobayashiS , TogiH , OhtomoE , GotoF , ArakiG , et al. Clinical usefulness of thrombin inhibitor MD-805 in acute phase of cerebral thrombosis - double blinded comparative study using placebo as a control (English translation). Igaku no Ayumi (Journal of Clinical and Experimental Medicine)1992;161:887-907. ">Tazaki 1992</a>; <a href="./references#CD000024-bbs2-0026" title="AdamsJHP . Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke1994;25:545. TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischaemic stroke. JAMA1998;279:1265-72. ">TOAST 1998</a>; <a href="./references#CD000024-bbs2-0027" title="TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1987;58:123. TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet1987;1:523-6. TurpieAGG . Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. Acta Chirurgica Scandinavica Supplementum1988;543:85-6. ">Turpie 1987</a>). Three trials performed CT for most patients (<a href="./references#CD000024-bbs2-0007" title="DukeRJ , TurpieAGG , BlochRF , DerbyIR , KronbyMH , BayerNH . Clinical trial of low-dose heparin for the prevention of stroke progression. Circulation1980;Suppl III:21. DukeRJ , TurpieAGG , BlochRF , TrebilcockRG . Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke-in-evolution. In: ReivichM , HurtigHI , editors(s). Cerebrovascular Disease. New York: Raven Press, 1983:399-405. ">Duke 1983</a>; <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>; <a href="./references#CD000024-bbs2-0028" title="VissingerH , HustedS . Trial of tinzaparin versus placebo in ischaemic stroke. Unpublished work. ">Vissinger 1995</a>): 81% of participants in <a href="./references#CD000024-bbs2-0007" title="DukeRJ , TurpieAGG , BlochRF , DerbyIR , KronbyMH , BayerNH . Clinical trial of low-dose heparin for the prevention of stroke progression. Circulation1980;Suppl III:21. DukeRJ , TurpieAGG , BlochRF , TrebilcockRG . Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke-in-evolution. In: ReivichM , HurtigHI , editors(s). Cerebrovascular Disease. New York: Raven Press, 1983:399-405. ">Duke 1983</a> were scanned; in <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>, 67% were scanned before randomisation, and 29% after randomisation, so that overall, 96% of participants were scanned; in <a href="./references#CD000024-bbs2-0028" title="VissingerH , HustedS . Trial of tinzaparin versus placebo in ischaemic stroke. Unpublished work. ">Vissinger 1995</a>, 66% of participants were scanned, and the remainder had cerebral scintigraphy to exclude haemorrhage. Three trials performed almost no CT scans (<a href="./references#CD000024-bbs2-0016" title="McCarthyST , TurnerJJ , RobertsonD , HawkeyCJ , MaceyDJ . Low dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet1977;ii:800-1. ">McCarthy 1977</a>; <a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a>; <a href="./references#CD000024-bbs2-0020" title="PinceJ . Thromboses veineuses des membres inferieurs et embolies pulmonaires au cours des accidents vasculaires cerebraux. A propos d'un essai comparitif de traitement preventif (These pour le doctorat d'etat en medecine). Toulouse: Universite Paul Sabatier, 1981. ">Pince 1981</a>), and two trials were undertaken before CT scanning was introduced (<a href="./references#CD000024-bbs2-0015" title="MarshallJ , ShawDA . Anticoagulant therapy in acute cerebrovascular accidents: a controlled trial. Lancet1960;1:995-8. MarshallJ , ShawDA . Anticoagulant therapy in cerebrovascular disease. In: Proceedings of the Royal Society of Medicine. 1960:547-9. ">Marshall 1960</a>; <a href="./references#CD000024-bbs2-0018" title="BakerRN , BrowardJA , FangHC , FisherCM , GrochSN , HeymanA , et al. Anticoagulant therapy in cerebral infarction. Report on co-operative study. Neurology1962;12:823-9. Miller FisherC . Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A national cooperative study, interim report. Neurology1961;11:119-31. ">NAT‐COOP 1962</a>). It is therefore likely that some people with intracerebral haemorrhage were inadvertently included in the main analyses of this review. This may have biased the results against anticoagulation if risks of anticoagulation are greater in those with intracerebral haemorrhage, although such bias is unlikely given the relatively small numbers of people with intracerebral haemorrhage involved in these trials, and because <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a> provided well over 80% of the overall data. </p> <p>Two trials included only participants with presumed cardioembolic stroke (<a href="./references#CD000024-bbs2-0004" title="HakimAM , FurlanAJ , HartRG . Immediate anticoagulation of embolic stroke: a randomized trial. The Cerebral Embolism Study Group. Stroke1983;14:668-76. HakimAM , Ryder-CookeA , MelansonD . Sequential computerized tomographic appearances of strokes. Stroke1983;14:893-7. ">CESG 1983</a>; <a href="./references#CD000024-bbs2-0018" title="BakerRN , BrowardJA , FangHC , FisherCM , GrochSN , HeymanA , et al. Anticoagulant therapy in cerebral infarction. Report on co-operative study. Neurology1962;12:823-9. Miller FisherC . Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A national cooperative study, interim report. Neurology1961;11:119-31. ">NAT‐COOP 1962</a>). One trial enrolled a subset of people with atrial fibrillation (<a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>), and detailed information on the effects of heparin in this subgroup was reported in a paper published in 2001 (<a href="./references#CD000024-bbs2-0165" title="SaxenaR , LewisS , BergeE , SandercockP , Koudstaal, P, the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7.">Saxena 2001</a>). </p> <p>The duration of follow‐up in included trials was generally short, although this was mainly a characteristic of the smaller trials, which contributed less to the overall analysis. Four trials in which the primary outcome of interest was deep vein thrombosis did not follow participants beyond 14 days (<a href="./references#CD000024-bbs2-0009" title="EliasA , MilandreL , LagrangeG , AillaudMF , AlonzoB , ToulemondeF , et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). Revue de Medecine Interne1990;11:95-8. ">Elias 1990</a>; <a href="./references#CD000024-bbs2-0016" title="McCarthyST , TurnerJJ , RobertsonD , HawkeyCJ , MaceyDJ . Low dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet1977;ii:800-1. ">McCarthy 1977</a>; <a href="./references#CD000024-bbs2-0020" title="PinceJ . Thromboses veineuses des membres inferieurs et embolies pulmonaires au cours des accidents vasculaires cerebraux. A propos d'un essai comparitif de traitement preventif (These pour le doctorat d'etat en medecine). Toulouse: Universite Paul Sabatier, 1981. ">Pince 1981</a>; <a href="./references#CD000024-bbs2-0021" title="PrinsMH , den OttolanderGJH , GelsemaR , vanWoerkomTCM , SingAK , HellerI . Deep venous thrombosis prophylaxis with a LMW heparin (KABI 2165) in stroke patients. Thrombosis and Haemostasis1987;58:117. PrinsMH , GelsemaR , SingAK , vanHeerdeLR , den OttolanderGJ . Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis1989;19:245-50. ">Prins 1989</a>), and only 14 trials followed participants longer than one month (<a href="./references#CD000024-bbs2-0001" title="LaMonteMP , NashML , WangDZ , WoolfendenAR , SchulzJ , HurstingMJ , et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1). Stroke2004;35:1677-82. ">ARGIS‐1 2004</a>; <a href="./references#CD000024-bbs2-0002" title="BarretoAD , FordGA , ShenL , PedrozaC , TysonJ , CaiC , et al. Randomized, multicenter trial of ARTSS-2 (Argatroban with Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke2017;48:1608-10. [PMID: 28507269]">ARTSS‐2 2017</a>; <a href="./references#CD000024-bbs2-0005" title="ChaudhryHR , AroraH , YadavK , DubeyS , GuptaR , JainR . Low molecular weight heparin In acute ischemic stroke. The Antiseptic2002;99:31-2. ">Chaudhary 2002</a>; <a href="./references#CD000024-bbs2-0006" title="DluhaJ , SivakS , KurcaE , DusenkaR , KalmarovaK , KoprusakovaMT , et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke - pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia2016;160:543-8. [PMID: 27646496]">Dluha 2016</a>; <a href="./references#CD000024-bbs2-0008" title="DukeRJ , BlochRF , TurpieAGG , TrebilcockRG , BayerN . Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Annals of Internal Medicine1986;105:825-8. DukeRJ , BlochRF , TurpieAGG . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:782. EastonJD , ShermanDG , HartRG . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:781. LoeligerEA . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:781-2. ">Duke 1986</a>; <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0011" title="HommelM , for the FISS-bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovascular Diseases1998;8 Suppl 4:19. ">FISS‐bis 1998</a>; <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>; <a href="./references#CD000024-bbs2-0013" title="KwiecinskiH , PniewskiJ , KaminskaA , SzylukB . A randomized trial of fraxiparine in acute ischaemic stroke. Cerebrovascular Diseases1995;5:234. ">Kwiecinski 1995</a>; <a href="./references#CD000024-bbs2-0014" title="LiuS , LiuP , WangP , ZhangF , Wang l, WangY , et al. Argatroban increased the basal vein drainage and improved outcomes in acute paraventricular ischemic stroke patients. Medical Science Monitor2020;26:e924593. ">Liu 2020</a>; <a href="./references#CD000024-bbs2-0015" title="MarshallJ , ShawDA . Anticoagulant therapy in acute cerebrovascular accidents: a controlled trial. Lancet1960;1:995-8. MarshallJ , ShawDA . Anticoagulant therapy in cerebrovascular disease. In: Proceedings of the Royal Society of Medicine. 1960:547-9. ">Marshall 1960</a>; <a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a>; <a href="./references#CD000024-bbs2-0026" title="AdamsJHP . Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke1994;25:545. TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischaemic stroke. JAMA1998;279:1265-72. ">TOAST 1998</a>; <a href="./references#CD000024-bbs2-0027" title="TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1987;58:123. TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet1987;1:523-6. TurpieAGG . Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. Acta Chirurgica Scandinavica Supplementum1988;543:85-6. ">Turpie 1987</a>). This lack of long‐term follow‐up is a weakness of many of the smaller studies, as a significant proportion of deaths after one month could have been due to stroke‐related thromboembolic events and might therefore have been prevented by early anticoagulation. Similarly, disability is best assessed when most of the recovery has taken place (i.e. between three and six months), rather than in the first week or so. </p> <p>Relatively few trials assessed the clinically most important outcome of long‐term functional status. Treatments that prevent death from stroke may lead to survival in a disabled state ‐ an outcome considered by many to be worse than death. The composite outcome of 'dead or dependent at follow‐up' is therefore the most important outcome in acute stroke trials. Eleven trials assessed this composite outcome. These trials contain data from well over 90% of the participants included in this review and evaluated the outcomes of death and dependency adequately (<a href="./references#CD000024-bbs2-0001" title="LaMonteMP , NashML , WangDZ , WoolfendenAR , SchulzJ , HurstingMJ , et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1). Stroke2004;35:1677-82. ">ARGIS‐1 2004</a>; <a href="./references#CD000024-bbs2-0002" title="BarretoAD , FordGA , ShenL , PedrozaC , TysonJ , CaiC , et al. Randomized, multicenter trial of ARTSS-2 (Argatroban with Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke2017;48:1608-10. [PMID: 28507269]">ARTSS‐2 2017</a>; <a href="./references#CD000024-bbs2-0003" title="CazzatoG , ZorzonM , MaseG , AntonuttoL , IonaLG . Mesoglycan in the treatment of acute cerebral infarction [Il mesoglicano nelle ischemie cerebrali acute a focolaio]. Rivista di Neurologia1989;59:121-6. ">Cazzato 1989</a>; <a href="./references#CD000024-bbs2-0005" title="ChaudhryHR , AroraH , YadavK , DubeyS , GuptaR , JainR . Low molecular weight heparin In acute ischemic stroke. The Antiseptic2002;99:31-2. ">Chaudhary 2002</a>; <a href="./references#CD000024-bbs2-0006" title="DluhaJ , SivakS , KurcaE , DusenkaR , KalmarovaK , KoprusakovaMT , et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke - pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia2016;160:543-8. [PMID: 27646496]">Dluha 2016</a>; <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0011" title="HommelM , for the FISS-bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovascular Diseases1998;8 Suppl 4:19. ">FISS‐bis 1998</a>; <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>; <a href="./references#CD000024-bbs2-0013" title="KwiecinskiH , PniewskiJ , KaminskaA , SzylukB . A randomized trial of fraxiparine in acute ischaemic stroke. Cerebrovascular Diseases1995;5:234. ">Kwiecinski 1995</a>; <a href="./references#CD000024-bbs2-0014" title="LiuS , LiuP , WangP , ZhangF , Wang l, WangY , et al. Argatroban increased the basal vein drainage and improved outcomes in acute paraventricular ischemic stroke patients. Medical Science Monitor2020;26:e924593. ">Liu 2020</a>; <a href="./references#CD000024-bbs2-0026" title="AdamsJHP . Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke1994;25:545. TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischaemic stroke. JAMA1998;279:1265-72. ">TOAST 1998</a>). Other important outcomes, including recurrent stroke or intracranial haemorrhage, were assessed but, once again, only by the more recent trials, which included large numbers of participants. Quality of life assessments were undertaken only in <a href="./references#CD000024-bbs2-0002" title="BarretoAD , FordGA , ShenL , PedrozaC , TysonJ , CaiC , et al. Randomized, multicenter trial of ARTSS-2 (Argatroban with Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke2017;48:1608-10. [PMID: 28507269]">ARTSS‐2 2017</a>. </p> </section> <section id="CD000024-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded 103 studies for a variety of reasons (see <a href="./references#CD000024-sec-0104" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD000024-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>Two review authors independently assessed risk of bias in all included studies across the following domains: random sequence generation and allocation concealment (selection bias); blinding of participants and personnel (performance bias); blinding of outcome assessment (detection bias); incomplete outcome data (attrition bias); selective reporting (reporting bias); and other potential sources of bias. </p> <p>See 'Risk of bias' tables in <a href="./references#CD000024-sec-0103" title="">Characteristics of included studies</a>, in the overall 'Risk of bias' graph (<a href="#CD000024-fig-0002">Figure 2</a>), and in the risk of bias summary (<a href="#CD000024-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD000024-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD000024-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD000024-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="original image" data-id="CD000024-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD000024-sec-0045"> <h4 class="title">Randomisation</h4> <p>There was marked variation in the quality of included trials. In 12 trials, the method of randomisation adequately prevented foreknowledge of treatment allocation; therefore they were at low risk. The remaining 16 trials had unclear risk. <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a> used a central telephone randomisation service. <a href="./references#CD000024-bbs2-0026" title="AdamsJHP . Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke1994;25:545. TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischaemic stroke. JAMA1998;279:1265-72. ">TOAST 1998</a> used permuted blocks to generate a randomisation list controlled by the hospital pharmacy. Eight trials utilised numbered or coded containers administered sequentially to enrolled participants (<a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0011" title="HommelM , for the FISS-bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovascular Diseases1998;8 Suppl 4:19. ">FISS‐bis 1998</a>; <a href="./references#CD000024-bbs2-0021" title="PrinsMH , den OttolanderGJH , GelsemaR , vanWoerkomTCM , SingAK , HellerI . Deep venous thrombosis prophylaxis with a LMW heparin (KABI 2165) in stroke patients. Thrombosis and Haemostasis1987;58:117. PrinsMH , GelsemaR , SingAK , vanHeerdeLR , den OttolanderGJ . Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis1989;19:245-50. ">Prins 1989</a>; <a href="./references#CD000024-bbs2-0022" title="SandsetPM , DahlT , AbildgaardU . Venous thromboembolic complications in acute thrombotic stroke. Progress report from a randomized trial. Acta Neurologia Scandinavica1987;76:392. SandsetPM , DahlT , StirisM , RostadB , ScheelB , AbildgaardU . A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Seminars in Thrombosis and Hemostasis1990;16 Suppl:25-33. ">Sandset 1990</a>; <a href="./references#CD000024-bbs2-0024" title="TazakiY , KobayashiS , TogiH , OhtomoE , GotoF , ArakiG , et al. Therapeutic effect of thrombin inhibitor MD-805 in acute phase of cerebral thrombosis - Phase II double-blinded clinical trial (English translation). Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine)1986;63:3047-57. ">Tazaki 1986</a>; <a href="./references#CD000024-bbs2-0025" title="TazakiY , KobayashiS , TogiH , OhtomoE , GotoF , ArakiG , et al. Clinical usefulness of thrombin inhibitor MD-805 in acute phase of cerebral thrombosis - double blinded comparative study using placebo as a control (English translation). Igaku no Ayumi (Journal of Clinical and Experimental Medicine)1992;161:887-907. ">Tazaki 1992</a>; <a href="./references#CD000024-bbs2-0027" title="TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1987;58:123. TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet1987;1:523-6. TurpieAGG . Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. Acta Chirurgica Scandinavica Supplementum1988;543:85-6. ">Turpie 1987</a>; <a href="./references#CD000024-bbs2-0028" title="VissingerH , HustedS . Trial of tinzaparin versus placebo in ischaemic stroke. Unpublished work. ">Vissinger 1995</a>). Three trials used random‐number tables controlled by an independent party (<a href="./references#CD000024-bbs2-0003" title="CazzatoG , ZorzonM , MaseG , AntonuttoL , IonaLG . Mesoglycan in the treatment of acute cerebral infarction [Il mesoglicano nelle ischemie cerebrali acute a focolaio]. Rivista di Neurologia1989;59:121-6. ">Cazzato 1989</a>; <a href="./references#CD000024-bbs2-0007" title="DukeRJ , TurpieAGG , BlochRF , DerbyIR , KronbyMH , BayerNH . Clinical trial of low-dose heparin for the prevention of stroke progression. Circulation1980;Suppl III:21. DukeRJ , TurpieAGG , BlochRF , TrebilcockRG . Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke-in-evolution. In: ReivichM , HurtigHI , editors(s). Cerebrovascular Disease. New York: Raven Press, 1983:399-405. ">Duke 1983</a>; <a href="./references#CD000024-bbs2-0008" title="DukeRJ , BlochRF , TurpieAGG , TrebilcockRG , BayerN . Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Annals of Internal Medicine1986;105:825-8. DukeRJ , BlochRF , TurpieAGG . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:782. EastonJD , ShermanDG , HartRG . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:781. LoeligerEA . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:781-2. ">Duke 1986</a>). The 2:1 treatment‐to‐control allocation ratio in <a href="./references#CD000024-bbs2-0027" title="TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1987;58:123. TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet1987;1:523-6. TurpieAGG . Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. Acta Chirurgica Scandinavica Supplementum1988;543:85-6. ">Turpie 1987</a>, <a href="./references#CD000024-bbs2-0024" title="TazakiY , KobayashiS , TogiH , OhtomoE , GotoF , ArakiG , et al. Therapeutic effect of thrombin inhibitor MD-805 in acute phase of cerebral thrombosis - Phase II double-blinded clinical trial (English translation). Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine)1986;63:3047-57. ">Tazaki 1986</a>, <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>, and <a href="./references#CD000024-bbs2-0011" title="HommelM , for the FISS-bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovascular Diseases1998;8 Suppl 4:19. ">FISS‐bis 1998</a> was deliberate. <a href="./references#CD000024-bbs2-0004" title="HakimAM , FurlanAJ , HartRG . Immediate anticoagulation of embolic stroke: a randomized trial. The Cerebral Embolism Study Group. Stroke1983;14:668-76. HakimAM , Ryder-CookeA , MelansonD . Sequential computerized tomographic appearances of strokes. Stroke1983;14:893-7. ">CESG 1983</a> used opaque sequentially numbered envelopes. The method of randomisation was unclear in 10 trials. Six trials stated that sealed envelopes were used, but in five of these, it is not clear whether or not the envelopes were opaque and sequentially numbered (<a href="./references#CD000024-bbs2-0009" title="EliasA , MilandreL , LagrangeG , AillaudMF , AlonzoB , ToulemondeF , et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). Revue de Medecine Interne1990;11:95-8. ">Elias 1990</a>; <a href="./references#CD000024-bbs2-0016" title="McCarthyST , TurnerJJ , RobertsonD , HawkeyCJ , MaceyDJ . Low dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet1977;ii:800-1. ">McCarthy 1977</a>; <a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a>; <a href="./references#CD000024-bbs2-0018" title="BakerRN , BrowardJA , FangHC , FisherCM , GrochSN , HeymanA , et al. Anticoagulant therapy in cerebral infarction. Report on co-operative study. Neurology1962;12:823-9. Miller FisherC . Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A national cooperative study, interim report. Neurology1961;11:119-31. ">NAT‐COOP 1962</a>; <a href="./references#CD000024-bbs2-0020" title="PinceJ . Thromboses veineuses des membres inferieurs et embolies pulmonaires au cours des accidents vasculaires cerebraux. A propos d'un essai comparitif de traitement preventif (These pour le doctorat d'etat en medecine). Toulouse: Universite Paul Sabatier, 1981. ">Pince 1981</a>). In <a href="./references#CD000024-bbs2-0019" title="DesmukhM , BisignaniM , LandauP , OrchardTJ . Deep vein thrombosis in rehabilitating stroke patients. Incidence, risk factors and prophylaxis. American Journal of Physical Medicine and Rehabilitation1991;70:313-6. PambiancoG , OrchardT , LandauP . Deep vein thrombosis: prevention in stroke patients during rehabilitation. Archives of Physical Medicine and Rehabilitation1995;76:324-30. ">Pambianco 1995</a>, the envelopes were not numbered. The exact method of randomisation was unknown in <a href="./references#CD000024-bbs2-0001" title="LaMonteMP , NashML , WangDZ , WoolfendenAR , SchulzJ , HurstingMJ , et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1). Stroke2004;35:1677-82. ">ARGIS‐1 2004</a>, <a href="./references#CD000024-bbs2-0005" title="ChaudhryHR , AroraH , YadavK , DubeyS , GuptaR , JainR . Low molecular weight heparin In acute ischemic stroke. The Antiseptic2002;99:31-2. ">Chaudhary 2002</a>, <a href="./references#CD000024-bbs2-0013" title="KwiecinskiH , PniewskiJ , KaminskaA , SzylukB . A randomized trial of fraxiparine in acute ischaemic stroke. Cerebrovascular Diseases1995;5:234. ">Kwiecinski 1995</a>, and <a href="./references#CD000024-bbs2-0015" title="MarshallJ , ShawDA . Anticoagulant therapy in acute cerebrovascular accidents: a controlled trial. Lancet1960;1:995-8. MarshallJ , ShawDA . Anticoagulant therapy in cerebrovascular disease. In: Proceedings of the Royal Society of Medicine. 1960:547-9. ">Marshall 1960</a>. </p> </section> <section id="CD000024-sec-0046"> <h4 class="title">Allocation</h4> <p>Twelve trials had low risk of bias, and the remaining 16 trials had unclear risk. Allocation concealment for the following small trials was unclear: <a href="./references#CD000024-bbs2-0001" title="LaMonteMP , NashML , WangDZ , WoolfendenAR , SchulzJ , HurstingMJ , et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1). Stroke2004;35:1677-82. ">ARGIS‐1 2004</a>, <a href="./references#CD000024-bbs2-0005" title="ChaudhryHR , AroraH , YadavK , DubeyS , GuptaR , JainR . Low molecular weight heparin In acute ischemic stroke. The Antiseptic2002;99:31-2. ">Chaudhary 2002</a>, <a href="./references#CD000024-bbs2-0009" title="EliasA , MilandreL , LagrangeG , AillaudMF , AlonzoB , ToulemondeF , et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). Revue de Medecine Interne1990;11:95-8. ">Elias 1990</a>, <a href="./references#CD000024-bbs2-0013" title="KwiecinskiH , PniewskiJ , KaminskaA , SzylukB . A randomized trial of fraxiparine in acute ischaemic stroke. Cerebrovascular Diseases1995;5:234. ">Kwiecinski 1995</a>, <a href="./references#CD000024-bbs2-0015" title="MarshallJ , ShawDA . Anticoagulant therapy in acute cerebrovascular accidents: a controlled trial. Lancet1960;1:995-8. MarshallJ , ShawDA . Anticoagulant therapy in cerebrovascular disease. In: Proceedings of the Royal Society of Medicine. 1960:547-9. ">Marshall 1960</a>, <a href="./references#CD000024-bbs2-0016" title="McCarthyST , TurnerJJ , RobertsonD , HawkeyCJ , MaceyDJ . Low dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet1977;ii:800-1. ">McCarthy 1977</a>, <a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a>, <a href="./references#CD000024-bbs2-0019" title="DesmukhM , BisignaniM , LandauP , OrchardTJ . Deep vein thrombosis in rehabilitating stroke patients. Incidence, risk factors and prophylaxis. American Journal of Physical Medicine and Rehabilitation1991;70:313-6. PambiancoG , OrchardT , LandauP . Deep vein thrombosis: prevention in stroke patients during rehabilitation. Archives of Physical Medicine and Rehabilitation1995;76:324-30. ">Pambianco 1995</a>, <a href="./references#CD000024-bbs2-0020" title="PinceJ . Thromboses veineuses des membres inferieurs et embolies pulmonaires au cours des accidents vasculaires cerebraux. A propos d'un essai comparitif de traitement preventif (These pour le doctorat d'etat en medecine). Toulouse: Universite Paul Sabatier, 1981. ">Pince 1981</a>, and <a href="./references#CD000024-bbs2-0023" title="SarmaGR , RoyAK . Nadroparin plus aspirin versus aspirin alone in the treatment of acute ischemic stroke. Neurology India2003;51:208-10. [PMID: 14571005]">Sarma 2003</a>. </p> </section> <section id="CD000024-sec-0047"> <h4 class="title">Blinding</h4> <p>Thirteen trials had low risk, six trials had high risk, and the remaining nine trials had unclear risk. Adequate blinding may be important to reduce bias in detection of deep vein thrombosis, pulmonary embolism, symptomatic intracranial haemorrhage, recurrent stroke, and functional outcome. Fifteen trials were double‐blind, that is, treatment allocation was concealed from participants, physicians, and outcome assessors (<a href="./references#CD000024-bbs2-0001" title="LaMonteMP , NashML , WangDZ , WoolfendenAR , SchulzJ , HurstingMJ , et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1). Stroke2004;35:1677-82. ">ARGIS‐1 2004</a>; <a href="./references#CD000024-bbs2-0002" title="BarretoAD , FordGA , ShenL , PedrozaC , TysonJ , CaiC , et al. Randomized, multicenter trial of ARTSS-2 (Argatroban with Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke2017;48:1608-10. [PMID: 28507269]">ARTSS‐2 2017</a>; <a href="./references#CD000024-bbs2-0006" title="DluhaJ , SivakS , KurcaE , DusenkaR , KalmarovaK , KoprusakovaMT , et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke - pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia2016;160:543-8. [PMID: 27646496]">Dluha 2016</a>; <a href="./references#CD000024-bbs2-0007" title="DukeRJ , TurpieAGG , BlochRF , DerbyIR , KronbyMH , BayerNH . Clinical trial of low-dose heparin for the prevention of stroke progression. Circulation1980;Suppl III:21. DukeRJ , TurpieAGG , BlochRF , TrebilcockRG . Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke-in-evolution. In: ReivichM , HurtigHI , editors(s). Cerebrovascular Disease. New York: Raven Press, 1983:399-405. ">Duke 1983</a>; <a href="./references#CD000024-bbs2-0008" title="DukeRJ , BlochRF , TurpieAGG , TrebilcockRG , BayerN . Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Annals of Internal Medicine1986;105:825-8. DukeRJ , BlochRF , TurpieAGG . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:782. EastonJD , ShermanDG , HartRG . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:781. LoeligerEA . Heparin in acute partial stable stroke. Annals of Internal Medicine1987;106:781-2. ">Duke 1986</a>; <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0011" title="HommelM , for the FISS-bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovascular Diseases1998;8 Suppl 4:19. ">FISS‐bis 1998</a>; <a href="./references#CD000024-bbs2-0014" title="LiuS , LiuP , WangP , ZhangF , Wang l, WangY , et al. Argatroban increased the basal vein drainage and improved outcomes in acute paraventricular ischemic stroke patients. Medical Science Monitor2020;26:e924593. ">Liu 2020</a>; <a href="./references#CD000024-bbs2-0021" title="PrinsMH , den OttolanderGJH , GelsemaR , vanWoerkomTCM , SingAK , HellerI . Deep venous thrombosis prophylaxis with a LMW heparin (KABI 2165) in stroke patients. Thrombosis and Haemostasis1987;58:117. PrinsMH , GelsemaR , SingAK , vanHeerdeLR , den OttolanderGJ . Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis1989;19:245-50. ">Prins 1989</a>; <a href="./references#CD000024-bbs2-0022" title="SandsetPM , DahlT , AbildgaardU . Venous thromboembolic complications in acute thrombotic stroke. Progress report from a randomized trial. Acta Neurologia Scandinavica1987;76:392. SandsetPM , DahlT , StirisM , RostadB , ScheelB , AbildgaardU . A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Seminars in Thrombosis and Hemostasis1990;16 Suppl:25-33. ">Sandset 1990</a>; <a href="./references#CD000024-bbs2-0024" title="TazakiY , KobayashiS , TogiH , OhtomoE , GotoF , ArakiG , et al. Therapeutic effect of thrombin inhibitor MD-805 in acute phase of cerebral thrombosis - Phase II double-blinded clinical trial (English translation). Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine)1986;63:3047-57. ">Tazaki 1986</a>; <a href="./references#CD000024-bbs2-0025" title="TazakiY , KobayashiS , TogiH , OhtomoE , GotoF , ArakiG , et al. Clinical usefulness of thrombin inhibitor MD-805 in acute phase of cerebral thrombosis - double blinded comparative study using placebo as a control (English translation). Igaku no Ayumi (Journal of Clinical and Experimental Medicine)1992;161:887-907. ">Tazaki 1992</a>; <a href="./references#CD000024-bbs2-0026" title="AdamsJHP . Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke1994;25:545. TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischaemic stroke. JAMA1998;279:1265-72. ">TOAST 1998</a>; <a href="./references#CD000024-bbs2-0027" title="TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1987;58:123. TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet1987;1:523-6. TurpieAGG . Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. Acta Chirurgica Scandinavica Supplementum1988;543:85-6. ">Turpie 1987</a>; <a href="./references#CD000024-bbs2-0028" title="VissingerH , HustedS . Trial of tinzaparin versus placebo in ischaemic stroke. Unpublished work. ">Vissinger 1995</a>), and in two other trials, deep vein thrombosis was assessed by radiologists blinded to treatment allocation (<a href="./references#CD000024-bbs2-0016" title="McCarthyST , TurnerJJ , RobertsonD , HawkeyCJ , MaceyDJ . Low dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet1977;ii:800-1. ">McCarthy 1977</a>; <a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a>). <a href="./references#CD000024-bbs2-0003" title="CazzatoG , ZorzonM , MaseG , AntonuttoL , IonaLG . Mesoglycan in the treatment of acute cerebral infarction [Il mesoglicano nelle ischemie cerebrali acute a focolaio]. Rivista di Neurologia1989;59:121-6. ">Cazzato 1989</a> had a blinded outcome assessor only. <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a> was not designed as a blinded study. However, an analysis of 207 participants from the UK enrolled in the IST pilot study showed that at six‐month follow‐up, a majority of participants could not remember whether or not they had been treated, and so these participants were effectively 'blinded' (<a href="./references#CD000024-bbs2-0159" title="LindleyRI . Are very large trials of promising treatments for acute stroke feasible?. Newcastle Upon Tyne: University of Newcastle Upon Tyne, 1993.">Lindley 1993</a>). In <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>, follow‐up data were collected by self‐completed questionnaire mailed to the participant six months after randomisation, or by telephone interview by a person blinded to treatment allocation. The remainder of the trials did not appear to use any form of blinded assessment. </p> </section> <section id="CD000024-sec-0048"> <h4 class="title">Incomplete outcome data</h4> <p>Twelve trials had low risk, nine trials had high risk, and the remaining seven trials had unclear risk. In total, only 218 participants (0.9% overall) were reported to be excluded from analysis after randomisation or were lost to follow‐up, with the vast majority of participants enrolled in studies in which an ITT analysis was performed. However, a number of participants in the smaller trials that did not report an ITT analysis may have been omitted from the analysis. </p> </section> <section id="CD000024-sec-0049"> <h4 class="title">Selective reporting</h4> <p>Twenty trials had low risk, one trial had high risk, and the remaining seven trials had unclear risk. We assessed risk of bias due to missing results in syntheses of primary outcomes most important to patients and health professionals (<a href="./references#CD000024-bbs2-0145" title="Boutron I, Page MJ, Higgins JT, Altman DG, Lundh A, Hróbjartsson A. Chapter 7. Considering bias and conflicts of interest among the included studies. In: Higgins JT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Boutron 2021</a>). There was no evidence of reporting bias. </p> </section> <section id="CD000024-sec-0050"> <h4 class="title">Other potential sources of bias</h4> <section id="CD000024-sec-0051"> <h5 class="title">Long‐term use of antiplatelet agents</h5> <p>In trials with follow‐up, differences in long‐term use of antiplatelet treatment between anticoagulant and control groups after hospital discharge may have biased the results, as antiplatelet treatment has been shown to reduce the risk of further vascular events by about 25% (<a href="./references#CD000024-bbs2-0143" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ2002;324:71-86.">ATC 2002</a>). Aspirin was given to all survivors in <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>. Aspirin was given to all patients without intracranial haemorrhage after 24 hours in <a href="./references#CD000024-bbs2-0006" title="DluhaJ , SivakS , KurcaE , DusenkaR , KalmarovaK , KoprusakovaMT , et al. The safety and efficacy of heparin and nadroparin compared to placebo in acute ischemic stroke - pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia2016;160:543-8. [PMID: 27646496]">Dluha 2016</a>. Long‐term treatment with aspirin was encouraged but was optional in several other trials, including <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>, <a href="./references#CD000024-bbs2-0011" title="HommelM , for the FISS-bis Investigators Group. Fraxiparine in Ischaemic Stroke Study (FISS bis). Cerebrovascular Diseases1998;8 Suppl 4:19. ">FISS‐bis 1998</a>, and <a href="./references#CD000024-bbs2-0026" title="AdamsJHP . Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke1994;25:545. TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischaemic stroke. JAMA1998;279:1265-72. ">TOAST 1998</a>. Aspirin (81 mg to 325 mg) was also used in both arms of the <a href="./references#CD000024-bbs2-0001" title="LaMonteMP , NashML , WangDZ , WoolfendenAR , SchulzJ , HurstingMJ , et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1). Stroke2004;35:1677-82. ">ARGIS‐1 2004</a> trial of the direct thrombin inhibitor argatroban. </p> </section> <section id="CD000024-sec-0052"> <h5 class="title">Imbalance at baseline</h5> <p>None of the trials reported significant imbalances in important baseline prognostic variables, although the small size of many suggests that they might be ruling out only substantial differences. </p> </section> </section> </section> <section id="CD000024-sec-0053"> <h3 class="title" id="CD000024-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD000024-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ Anticoagulant compared to control in acute presumed ischaemic stroke</a> </p> <section id="CD000024-sec-0054"> <h4 class="title">Outcome 1.1: Dead or dependent at end of follow‐up more than one month after randomisation</h4> <p>Twelve trials including randomised data from 22,428 participants (93.3% of participants included in the overall review) evaluated death and long‐term disability. The degree of dependence was determined by noting whether participants required help from other people for their activities of daily living at the time of final follow‐up. Treatment with early anticoagulation was not associated with a significant reduction in the odds of death or dependence at final follow up (odds ratio (OR) 0.98, 95% confidence interval (CI) 0.92 to 1.03; P = 0.37; 12 RCTs, 22,428 participants; high‐certainty evidence; <a href="./references#CD000024-fig-0007" title="">Analysis 1.1</a>). However, substantial heterogeneity of treatment effect (I² = 64%) was evident between the different regimens included. </p> <section id="CD000024-sec-0055"> <h5 class="title">Subgroup analyses</h5> <section id="CD000024-sec-0056"> <h6 class="title">By type of anticoagulant agent used</h6> <p>There were no significant differences in death or dependence between subgroups of different anticoagulant agents (P = 0.12; moderate‐certainty evidence; <a href="./references#CD000024-fig-0016" title="">Analysis 1.10</a>). </p> </section> <section id="CD000024-sec-0057"> <h6 class="title">By anticoagulant dose</h6> <p>There was no statistically significant difference in death or dependence at final follow‐up between trials (P = 0.65; moderate‐certainty evidence; <a href="./references#CD000024-fig-0017" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD000024-sec-0058"> <h5 class="title">Sensitivity analyses</h5> <p>Sensitivity analyses were restricted to:</p> <p> <ul id="CD000024-list-0012"> <li> <p>trials in which the method of randomisation ensured adequate concealment of treatment allocation, which showed that all trials evaluating death and dependence at final follow‐up had adequate concealment of the randomisation process (<a href="./references#CD000024-fig-0018" title="">Analysis 1.12</a>); </p> </li> <li> <p>trials that restricted entry to the study to within 48 hours of stroke onset, which showed that all trials evaluating death or dependence at final follow‐up enrolled participants within 48 hours of stroke onset (<a href="./references#CD000024-fig-0019" title="">Analysis 1.13</a>). Within <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>, there was no evidence that the effect of treatment was increased or decreased with increasing delay to randomisation up to 48 hours; </p> </li> <li> <p>trials other than <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a> (since it contained most of the data important for the review), which showed an apparent difference in effects of treatment on death or dependence at final follow‐up if data from IST were included (OR 0.98, 95% CI 0.93 to 1.03; P = 0.41; 11 RCTs, 22,368 participants; high‐certainty evidence; <a href="./references#CD000024-fig-0007" title="">Analysis 1.1</a>)) or excluded (OR 0.82, 95% CI.70 to 0.96; P = 0.01; 10 RCTs, 2933 participants; moderate‐certainty evidence; <a href="./references#CD000024-fig-0020" title="">Analysis 1.14</a>); and </p> </li> <li> <p>a post‐hoc sensitivity analysis to assess the impact of duration of follow‐up on the estimate of effect for the primary outcome, with exclusion of the trial with assessment of the primary outcome after only one month, which had no impact on overall estimate of effect (OR 0.98, 95% CI 0.92 to 1.03; P = 0.42; 11 RCTs, 22,371 participants; high‐certainty evidence; <a href="./references#CD000024-fig-0021" title="">Analysis 1.15</a>) nor on degree of heterogeneity (I² = 65%) (<a href="./references#CD000024-bbs2-0003" title="CazzatoG , ZorzonM , MaseG , AntonuttoL , IonaLG . Mesoglycan in the treatment of acute cerebral infarction [Il mesoglicano nelle ischemie cerebrali acute a focolaio]. Rivista di Neurologia1989;59:121-6. ">Cazzato 1989</a>). </p> </li> </ul> </p> </section> </section> <section id="CD000024-sec-0059"> <h4 class="title">Outcome 1.2: Death from all causes during the scheduled treatment period</h4> <p>Data from 22 trials, which included randomised data from 22,602 participants (94.3% of participants included in the review), were available for this outcome. Anticoagulants were not associated with a significant reduction in death at the end of the treatment period (OR 0.99, 95% CI 0.90 to 1.09; P = 0.88; 22 RCTs, 22,602 participants; low‐certainty evidence; <a href="./references#CD000024-fig-0008" title="">Analysis 1.2</a>). There was no significant heterogeneity (I² = 16%). </p> </section> <section id="CD000024-sec-0060"> <h4 class="title">Outcome 1.3: Death from all causes at final follow‐up more than one month after randomisation</h4> <p>Data were available for 15 trials, which included 23,079 participants (96.1 % of participants included in the overall review). Anticoagulants were not associated with any significant reduction in the odds of death at final follow‐up greater than one month (OR 1.05, 95% CI 0.98 to 1.12; P = 0.17; I² = 15%; 15 RCTs, 23,079 participants; moderate‐certainty evidence; <a href="./references#CD000024-fig-0009" title="">Analysis 1.3</a>). </p> </section> <section id="CD000024-sec-0061"> <h4 class="title">Outcome 1.4: Deep vein thrombosis during the treatment period</h4> <p>Ten trials, which included randomised data from 916 participants (only 3.8% of participants included in the overall review), sought to systematically determine the effect of anticoagulants on occurrence of 'symptomatic or asymptomatic deep vein thrombosis' at the end of the treatment period, as detected by: </p> <p> <ul id="CD000024-list-0013"> <li> <p>I‐125 fibrinogen scanning (<a href="./references#CD000024-bbs2-0007" title="DukeRJ , TurpieAGG , BlochRF , DerbyIR , KronbyMH , BayerNH . Clinical trial of low-dose heparin for the prevention of stroke progression. Circulation1980;Suppl III:21. DukeRJ , TurpieAGG , BlochRF , TrebilcockRG . Clinical trial of low-dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke-in-evolution. In: ReivichM , HurtigHI , editors(s). Cerebrovascular Disease. New York: Raven Press, 1983:399-405. ">Duke 1983</a>; <a href="./references#CD000024-bbs2-0009" title="EliasA , MilandreL , LagrangeG , AillaudMF , AlonzoB , ToulemondeF , et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). Revue de Medecine Interne1990;11:95-8. ">Elias 1990</a>; <a href="./references#CD000024-bbs2-0016" title="McCarthyST , TurnerJJ , RobertsonD , HawkeyCJ , MaceyDJ . Low dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet1977;ii:800-1. ">McCarthy 1977</a>; <a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a>; <a href="./references#CD000024-bbs2-0020" title="PinceJ . Thromboses veineuses des membres inferieurs et embolies pulmonaires au cours des accidents vasculaires cerebraux. A propos d'un essai comparitif de traitement preventif (These pour le doctorat d'etat en medecine). Toulouse: Universite Paul Sabatier, 1981. ">Pince 1981</a>; <a href="./references#CD000024-bbs2-0021" title="PrinsMH , den OttolanderGJH , GelsemaR , vanWoerkomTCM , SingAK , HellerI . Deep venous thrombosis prophylaxis with a LMW heparin (KABI 2165) in stroke patients. Thrombosis and Haemostasis1987;58:117. PrinsMH , GelsemaR , SingAK , vanHeerdeLR , den OttolanderGJ . Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis1989;19:245-50. ">Prins 1989</a>; <a href="./references#CD000024-bbs2-0027" title="TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1987;58:123. TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet1987;1:523-6. TurpieAGG . Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. Acta Chirurgica Scandinavica Supplementum1988;543:85-6. ">Turpie 1987</a>); </p> </li> <li> <p>B‐mode and Doppler ultrasound (<a href="./references#CD000024-bbs2-0019" title="DesmukhM , BisignaniM , LandauP , OrchardTJ . Deep vein thrombosis in rehabilitating stroke patients. Incidence, risk factors and prophylaxis. American Journal of Physical Medicine and Rehabilitation1991;70:313-6. PambiancoG , OrchardT , LandauP . Deep vein thrombosis: prevention in stroke patients during rehabilitation. Archives of Physical Medicine and Rehabilitation1995;76:324-30. ">Pambianco 1995</a>); or </p> </li> <li> <p>X‐ray contrast venography (<a href="./references#CD000024-bbs2-0022" title="SandsetPM , DahlT , AbildgaardU . Venous thromboembolic complications in acute thrombotic stroke. Progress report from a randomized trial. Acta Neurologia Scandinavica1987;76:392. SandsetPM , DahlT , StirisM , RostadB , ScheelB , AbildgaardU . A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Seminars in Thrombosis and Hemostasis1990;16 Suppl:25-33. ">Sandset 1990</a>; <a href="./references#CD000024-bbs2-0028" title="VissingerH , HustedS . Trial of tinzaparin versus placebo in ischaemic stroke. Unpublished work. ">Vissinger 1995</a>). </p> </li> </ul> </p> <p>Despite the small numbers of participants studied, anticoagulation was associated with a highly significant reduction in the odds of deep vein thrombosis (OR 0.21, 95% CI 0.15 to 0.29; P &lt; 0.00001; 10 RCTs, 916 participants; low‐certainty evidence; <a href="./references#CD000024-fig-0010" title="">Analysis 1.4</a>), although a majority of deep vein thromboses detected were subclinical and asymptomatic. </p> <p>There was substantial heterogeneity between trial results (I² = 72%), which appeared to be due to three trials that did not show any clear effect of anticoagulation on the odds of deep vein thrombosis (<a href="./references#CD000024-bbs2-0019" title="DesmukhM , BisignaniM , LandauP , OrchardTJ . Deep vein thrombosis in rehabilitating stroke patients. Incidence, risk factors and prophylaxis. American Journal of Physical Medicine and Rehabilitation1991;70:313-6. PambiancoG , OrchardT , LandauP . Deep vein thrombosis: prevention in stroke patients during rehabilitation. Archives of Physical Medicine and Rehabilitation1995;76:324-30. ">Pambianco 1995</a>; <a href="./references#CD000024-bbs2-0022" title="SandsetPM , DahlT , AbildgaardU . Venous thromboembolic complications in acute thrombotic stroke. Progress report from a randomized trial. Acta Neurologia Scandinavica1987;76:392. SandsetPM , DahlT , StirisM , RostadB , ScheelB , AbildgaardU . A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Seminars in Thrombosis and Hemostasis1990;16 Suppl:25-33. ">Sandset 1990</a>; <a href="./references#CD000024-bbs2-0028" title="VissingerH , HustedS . Trial of tinzaparin versus placebo in ischaemic stroke. Unpublished work. ">Vissinger 1995</a>), as well as two trials that did (<a href="./references#CD000024-bbs2-0009" title="EliasA , MilandreL , LagrangeG , AillaudMF , AlonzoB , ToulemondeF , et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). Revue de Medecine Interne1990;11:95-8. ">Elias 1990</a>; <a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a>). The three negative trials were the only ones that did not use I‐125 fibrinogen scanning. One used ultrasound assessment (<a href="./references#CD000024-bbs2-0019" title="DesmukhM , BisignaniM , LandauP , OrchardTJ . Deep vein thrombosis in rehabilitating stroke patients. Incidence, risk factors and prophylaxis. American Journal of Physical Medicine and Rehabilitation1991;70:313-6. PambiancoG , OrchardT , LandauP . Deep vein thrombosis: prevention in stroke patients during rehabilitation. Archives of Physical Medicine and Rehabilitation1995;76:324-30. ">Pambianco 1995</a>), and the other two used venography (<a href="./references#CD000024-bbs2-0022" title="SandsetPM , DahlT , AbildgaardU . Venous thromboembolic complications in acute thrombotic stroke. Progress report from a randomized trial. Acta Neurologia Scandinavica1987;76:392. SandsetPM , DahlT , StirisM , RostadB , ScheelB , AbildgaardU . A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Seminars in Thrombosis and Hemostasis1990;16 Suppl:25-33. ">Sandset 1990</a>; <a href="./references#CD000024-bbs2-0028" title="VissingerH , HustedS . Trial of tinzaparin versus placebo in ischaemic stroke. Unpublished work. ">Vissinger 1995</a>). In addition, in one of these trials, participants were randomised up to 14 days after their initial stroke (<a href="./references#CD000024-bbs2-0019" title="DesmukhM , BisignaniM , LandauP , OrchardTJ . Deep vein thrombosis in rehabilitating stroke patients. Incidence, risk factors and prophylaxis. American Journal of Physical Medicine and Rehabilitation1991;70:313-6. PambiancoG , OrchardT , LandauP . Deep vein thrombosis: prevention in stroke patients during rehabilitation. Archives of Physical Medicine and Rehabilitation1995;76:324-30. ">Pambianco 1995</a>), whereas all other trials randomised participants within seven days. The two most positive trials had very small numbers of participants, with the resultant possibility that the results may have been due to chance. In addition, <a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a> (the most positive trial) was poorly concealed, introducing another potential source of bias. </p> <p>Sensitivity analyses showed there was no significant difference in the reduction in deep vein thrombosis from the above result if the analysis was restricted to trials in which concealment of allocation was secure (OR 0.32, 95% CI 0.15 to 0.68; I² = 53%; P = 0.003; 3 RCTs, 282 participants; low‐certainty evidence; <a href="./references#CD000024-fig-0022" title="">Analysis 1.16</a>) or trials in which radiographic assessment was blinded (OR 0.44, 95% CI 0.27 to 0.72; I² = 51%; P = 0.0007; 6 RCTs, 499 participants; low‐certainty evidence; <a href="./references#CD000024-fig-0023" title="">Analysis 1.17</a>). One of the trials excluded from this review did provide data on the numbers of deep vein thromboses in participants by allocated treatment group (1/19 heparin, 3/27 placebo), but inclusion of these results did not significantly alter the analysis (<a href="./references#CD000024-bbs2-0043" title="DahanR , HoulbertD , CaulinC , CuzinE , ViltartC , WolerM , et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis1986;16:159-64. ">Dahan 1986</a>). No trials systematically sought to assess deep vein thrombosis after completion of treatment. </p> </section> <section id="CD000024-sec-0062"> <h4 class="title">Outcome 1.5: Recurrent ischaemic stroke or recurrent stroke of unknown pathological type during the treatment period </h4> <p>Twelve trials, which included 21,665 participants (90.2% of participants included in the overall review), systematically sought to record early recurrent strokes that were definitely ischaemic (CT scan excluded haemorrhage) or probably ischaemic, that is, in which the cerebral pathology was unknown because a CT scan had not been performed. Anticoagulation was associated with a statistically significant reduction in recurrent ischaemic stroke (OR 0.75, 95% CI 0.65 to 0.88; P =0.0003; 12 RCTs, 21,605 participants; moderate‐certainty evidence; I² = 0, <a href="./references#CD000024-fig-0011" title="">Analysis 1.5</a>). Most data (95%) were obtained from <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>. </p> </section> <section id="CD000024-sec-0063"> <h4 class="title">Outcome 1.6: Symptomatic intracranial haemorrhage during the treatment period</h4> <p>Twenty trials, which included randomised data from 23,221 participants (96.7% of participants included in the overall review), reported data on symptomatic (fatal and non‐fatal) intracranial haemorrhage confirmed by CT scanning or autopsy. Early anticoagulation significantly increased symptomatic intracranial haemorrhage more than twofold (OR 2.47, 95% CI 1.90 to 3.21; P &lt; 0.00001; 20 RCTs, 23,221 participants; high‐certainty evidence; I² = 0, <a href="./references#CD000024-fig-0012" title="">Analysis 1.6</a>). Most data (76%) were contributed by <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>. </p> <p>No significant heterogeneity was apparent in the excess of haemorrhage with different types of heparin. However, within <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>, intracranial haemorrhage significantly increased with increasing heparin dose. Participants allocated to avoid heparin, low‐dose heparin, and medium‐dose heparin had rates of intracranial haemorrhage of 0.3%, 0.7%, and 1.8%, respectively. </p> <p>There is the possibility of some bias within these data, as there may have been a lower threshold for re‐scanning participants who had deteriorated clinically if they were known to be receiving anticoagulants (e.g. in <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>, which was not blinded). In addition, even in blinded trials, a physician is likely to be unblinded if bruising is observed at heparin injection sites. An unbiased assessment of the effect of anticoagulants on the occurrence of intracranial haemorrhage would come from systematic studies in which all participants undergo a CT scan before the start of treatment to exclude haemorrhage, and all survivors have a repeat CT scan at the end of the scheduled treatment period, regardless of their clinical status. In such an unbiased assessment, all participants who died during the study would have to undergo an autopsy. Unfortunately, it is rarely possible to achieve repeat CT scans in all survivors, or autopsies in all deaths. Five trials in this review made a systematic attempt to detect both symptomatic and asymptomatic intracranial haemorrhage in this way (<a href="./references#CD000024-bbs2-0001" title="LaMonteMP , NashML , WangDZ , WoolfendenAR , SchulzJ , HurstingMJ , et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1). Stroke2004;35:1677-82. ">ARGIS‐1 2004</a>; <a href="./references#CD000024-bbs2-0004" title="HakimAM , FurlanAJ , HartRG . Immediate anticoagulation of embolic stroke: a randomized trial. The Cerebral Embolism Study Group. Stroke1983;14:668-76. HakimAM , Ryder-CookeA , MelansonD . Sequential computerized tomographic appearances of strokes. Stroke1983;14:893-7. ">CESG 1983</a>; <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0021" title="PrinsMH , den OttolanderGJH , GelsemaR , vanWoerkomTCM , SingAK , HellerI . Deep venous thrombosis prophylaxis with a LMW heparin (KABI 2165) in stroke patients. Thrombosis and Haemostasis1987;58:117. PrinsMH , GelsemaR , SingAK , vanHeerdeLR , den OttolanderGJ . Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis1989;19:245-50. ">Prins 1989</a>; <a href="./references#CD000024-bbs2-0022" title="SandsetPM , DahlT , AbildgaardU . Venous thromboembolic complications in acute thrombotic stroke. Progress report from a randomized trial. Acta Neurologia Scandinavica1987;76:392. SandsetPM , DahlT , StirisM , RostadB , ScheelB , AbildgaardU . A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Seminars in Thrombosis and Hemostasis1990;16 Suppl:25-33. ">Sandset 1990</a>). All of the confirmed intracranial haemorrhages were intracerebral. In <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>, the use of systematic CT scanning was introduced during the trial, and so not all participants were eligible for this analysis. However, the numbers of participants and events in this analysis were small (symptomatic plus asymptomatic haemorrhages occurring in 20/266 participants (7.5%) allocated to anticoagulant versus 27/264 control participants (10.2%)), so the estimate of risk of 'symptomatic plus asymptomatic' haemorrhage is imprecise (OR 0.76, 95% CI 0.38 to 1.52; <a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>). In this trial, 25 participants (5% overall, 15 treated versus 10 control) did not have a repeat CT scan or autopsy (<a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>). Including these 25 participants in hypothetical best‐ and worst‐case analyses changed the odds ratio significantly (OR 0.44 and 1.44 respectively), which suggests that the results are compatible with substantial reductions or increases in the risk of 'symptomatic plus asymptomatic' intracranial haemorrhage with treatment. </p> </section> <section id="CD000024-sec-0064"> <h4 class="title">Outcome 1.7: Any recurrent stroke or symptomatic intracranial haemorrhage during the treatment period and during long‐term follow‐up </h4> <p>Early anticoagulation reduces the odds of ischaemic stroke but also increases the odds of symptomatic intracranial haemorrhage. An outcome that combines these two (without double counting ‐ i.e. each participant is counted only once, even if both events occurred, with the first event being the one that is included) is useful for assessing the net short‐term effects of anticoagulants. Twelve trials, which included randomised data from 21,665 participants (90.2% of participants included in the overall review), evaluated the occurrence of 'any recurrent stroke or symptomatic intracranial haemorrhage' during the treatment period. Anticoagulation was not associated with a net reduction in the odds of this outcome (OR 0.97, 95% CI 0.84 to 1.11; P = 0.64; 12 RCTs, 21,665 participants; moderate‐certainty evidence; I² = 28%; <a href="./references#CD000024-fig-0013" title="">Analysis 1.7</a>). Most of the data (93.6%) were obtained from <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>. An analysis of recurrent stroke or intracranial haemorrhage during the follow‐up period could only include data from three small studies (<a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0015" title="MarshallJ , ShawDA . Anticoagulant therapy in acute cerebrovascular accidents: a controlled trial. Lancet1960;1:995-8. MarshallJ , ShawDA . Anticoagulant therapy in cerebrovascular disease. In: Proceedings of the Royal Society of Medicine. 1960:547-9. ">Marshall 1960</a>; <a href="./references#CD000024-bbs2-0027" title="TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1987;58:123. TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet1987;1:523-6. TurpieAGG . Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. Acta Chirurgica Scandinavica Supplementum1988;543:85-6. ">Turpie 1987</a>). Events were far too few for a reliable analysis. </p> </section> <section id="CD000024-sec-0065"> <h4 class="title">Outcome 1.8: Symptomatic pulmonary embolism during the treatment period</h4> <p>Fourteen trials, which included data from 22,544 participants (95.7% of participants included in the overall review), assessed reported fatal and non‐fatal symptomatic pulmonary embolism, but no trial had systematically sought asymptomatic pulmonary embolism by performing ventilation‐perfusion scans in all participants at the end of the treatment period. Anticoagulation was associated with a significant reduction in the odds of pulmonary embolism (OR 0.60, 95% CI 0.44 to 0.81; P = 0.0009; 14 RCTs, 22,544 participants; moderate‐certainty evidence; I² = 13.7%; <a href="./references#CD000024-fig-0014" title="">Analysis 1.8</a>). </p> <p>In the trials described, the frequency of pulmonary embolism during the treatment period was variable but was quite low (1% in <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a> versus 7% in <a href="./references#CD000024-bbs2-0009" title="EliasA , MilandreL , LagrangeG , AillaudMF , AlonzoB , ToulemondeF , et al. Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients). Revue de Medecine Interne1990;11:95-8. ">Elias 1990</a> and <a href="./references#CD000024-bbs2-0021" title="PrinsMH , den OttolanderGJH , GelsemaR , vanWoerkomTCM , SingAK , HellerI . Deep venous thrombosis prophylaxis with a LMW heparin (KABI 2165) in stroke patients. Thrombosis and Haemostasis1987;58:117. PrinsMH , GelsemaR , SingAK , vanHeerdeLR , den OttolanderGJ . Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis1989;19:245-50. ">Prins 1989</a>). Although not reported systematically, and thereby potentially under‐reported, the rate of pulmonary embolism in <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a> among participants not receiving heparin was only 0.8%. This observation is supported by data from prospective hospital‐based studies that have reported symptomatic pulmonary embolism as a complication in between 1% and 3% of patients with acute stroke (<a href="./references#CD000024-bbs2-0149" title="DavenportR , DennisM , WellwoodI , WarlowC . Complications after acute stroke. Stroke1996;27:415-20.">Davenport 1996</a>). </p> <p>Patients may continue to be at risk of pulmonary embolism after the early treatment period. This was suggested by data from three trials that continued to seek events systematically during the follow‐up period (<a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0026" title="AdamsJHP . Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke1994;25:545. TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischaemic stroke. JAMA1998;279:1265-72. ">TOAST 1998</a>; <a href="./references#CD000024-bbs2-0027" title="TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1987;58:123. TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet1987;1:523-6. TurpieAGG . Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. Acta Chirurgica Scandinavica Supplementum1988;543:85-6. ">Turpie 1987</a>). Eight further pulmonary emboli were recorded, six of which occurred in the control group. The potential use of antiplatelet or anticoagulant agents after the trial period may have influenced the results of several trials (<a href="./references#CD000024-bbs2-0010" title="KayR , WongKS , LuYL , ChanYW , TsoiTH , AhujaAT , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New England Journal of Medicine1995;333:1588-93. KayR . Fraxiparin in stroke study. Stroke1994;25:253. ">FISS 1995</a>; <a href="./references#CD000024-bbs2-0026" title="AdamsJHP . Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke1994;25:545. TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischaemic stroke. JAMA1998;279:1265-72. ">TOAST 1998</a>; <a href="./references#CD000024-bbs2-0027" title="TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. A double-blind randomized trial of Org 10172 low molecular weight heparinoid in the prevention of deep venous thrombosis in patients with thrombotic stroke. Thrombosis and Haemostasis1987;58:123. TurpieAGG , LevineMN , HirshJ , CarterCJ , JayRM , PowersPJ , et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet1987;1:523-6. TurpieAGG . Low molecular weight heparins: deep vein thrombosis prophylaxis in elective hip surgery and thrombotic stroke. Acta Chirurgica Scandinavica Supplementum1988;543:85-6. ">Turpie 1987</a>). One trial, with an 80% autopsy rate, did show a significant reduction in the risk of symptomatic and asymptomatic pulmonary embolism detected at autopsy in the anticoagulation group (7/24 versus 33/47; OR 0.19, 95% CI 0.07 to 0.52) (<a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a>). </p> </section> <section id="CD000024-sec-0066"> <h4 class="title">Outcome 1.9: Major extracranial haemorrhage during the treatment period</h4> <p>Eighteen trials, which included randomised data from 22,255 participants (93.7 % of participants included in the overall review), reported data on major extracranial haemorrhage (defined as bleeding serious enough to cause death or to require hospitalisation or transfusion). Anticoagulation was associated with a significant threefold increase in major extracranial haemorrhage (OR 2.99, 95% CI 2.24 to 3.99; P &lt; 0.00001; 18 RCTs, 22,255 participants; moderate‐certainty evidence; I² = 4%; <a href="./references#CD000024-fig-0015" title="">Analysis 1.9</a>). </p> </section> <section id="CD000024-sec-0067"> <h4 class="title">Publication bias</h4> <p>To determine whether or not we might have missed an important number of small negative trials (these are the trials most likely to remain unpublished), we undertook a funnel plot analysis (<a href="./references#CD000024-bbs2-0151" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629-34.">Egger 1997</a>). Analyses with the greatest number of trials included (and hence the greatest statistical power) examined effects of treatment on death during the treatment period (<a href="#CD000024-fig-0004">Figure 4</a>), death from all causes at final follow‐up (<a href="#CD000024-fig-0005">Figure 5</a>), and deep vein thrombosis (<a href="#CD000024-fig-0006">Figure 6</a>). For these outcomes, a plot of the sample size for each trial versus the odds ratio for that trial showed an approximate 'funnel distribution' with 'tails' in both positive and negative treatment effect directions (except for the outcome of deep vein thrombosis), indicating that we were unlikely to have missed a substantial number of negative trials. </p> <div class="figure" id="CD000024-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD000024-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD000024-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="original image" data-id="CD000024-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD000024-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="original image" data-id="CD000024-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000024-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000024-sec-0068"></div> <p>The evidence provided in this updated systematic review has not changed any of the conclusions of the previous review published in 2015, and can be summarised as follows. </p> <section id="CD000024-sec-0069"> <h3 class="title" id="CD000024-sec-0069">Summary of main results</h3> <section id="CD000024-sec-0070"> <h4 class="title">Net effect of early anticoagulants in acute ischaemic stroke</h4> <p>Acute stroke treatment should aim to prevent disability as well as death, lest patients survive their acute stroke only to remain severely disabled. Currently available evidence from randomised trials indicates that routine early anticoagulation does not provide any significant net short‐term or long‐term reduction in death or disability. Although early anticoagulation leads to fewer recurrent ischaemic strokes, this benefit is entirely offset by a similarly sized increase in intracranial haemorrhage. The net result is no short‐term or long‐term benefit. </p> </section> <section id="CD000024-sec-0071"> <h4 class="title">Hazards of early anticoagulants in acute ischaemic stroke</h4> <p>To be useful, a medical therapy must be safe. Current evidence from randomised trials demonstrates a clinically and statistically significant risk of major intracranial and extracranial haemorrhage with early use of anticoagulants for people with acute ischaemic stroke. </p> </section> <section id="CD000024-sec-0072"> <h4 class="title">Different anticoagulant agents ‐ doses and routes of administration</h4> <p>Low‐molecular‐weight heparin and unfractionated intravenous heparin are not effective in reducing the risk of death or dependency, nor death, during the treatment period, or after follow‐up greater than one month. Other types of agents of unfractionated subcutaneous heparin, heparinoids, and specific thrombin inhibitors have shown no significant net benefit in terms of reducing death during the treatment period, nor death or dependency after follow‐up greater than one month. Direct comparisons of different anticoagulants show no clear benefit of heparinoids versus unfractionated heparin (<a href="./references#CD000024-bbs2-0164" title="SandercockPAG , CounsellC , TsengMC . Low molecular weight heparin or heparinoids versus standard unfractionated heparin for acute ischemic stroke. Cochrane Database of Systematic Reviews2008, Issue 3. Art. No: CD000119. [DOI: 10.1002/14651858.CD000119.pub3]">Sandercock 2008</a>). Available evidence does not support the routine use of adjusted‐dose intravenous heparin (or heparinoid) regimens, or of more intensive fixed‐dose regimens. </p> </section> <section id="CD000024-sec-0073"> <h4 class="title">Prevention of deep vein thrombosis and pulmonary embolism in acute ischaemic stroke with anticoagulants </h4> <p>For participants with presumed or confirmed ischaemic stroke, allocation to early anticoagulation was associated with a highly significant 79% reduction in the odds of deep vein thrombosis during the treatment period ‐ similar to that seen with the use of prophylactic heparin for people undergoing different types of surgery (<a href="./references#CD000024-bbs2-0147" title="CollinsR , ScrimgeourA , YusufS , PetoR . Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. New England Journal of Medicine1988;318:1162-73.">Collins 1988</a>). In this review, the reductions in deep vein thrombosis with acute anticoagulation were statistically significant, although this estimate is based on relatively small numbers of participants, and most of the deep vein thromboses detected were asymptomatic. Heterogeneity in the effects of treatment is significant, which renders the overall estimate less reliable. </p> <p>The clinical significance of this reduction depends critically on the control event rate. In included studies, there was substantial variation in the control event rate, from 13% in <a href="./references#CD000024-bbs2-0028" title="VissingerH , HustedS . Trial of tinzaparin versus placebo in ischaemic stroke. Unpublished work. ">Vissinger 1995</a> to 73% in <a href="./references#CD000024-bbs2-0017" title="McCarthyST , TurnerJ . Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing1986;15:84-8. ">McCarthy 1986</a>. The rate will depend on many factors such as severity of stroke, presence of leg paralysis, and history of previous deep vein thrombosis (<a href="./references#CD000024-bbs2-0167" title="WarlowC , BamfordJ , DennisM , RothwellP , RinkelG , SandercockP , et al. Stroke: Practical Management. 3rd edition. Blackwells Scientific, 2008.">Warlow 2008</a>). The odds of pulmonary embolism were reduced significantly (by 40%) with the use of anticoagulants. In the included trials, pulmonary embolism was uncommon, so assuming the 0.8% control rate seen in the largest trial with the most representative sample of participants (<a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>), the number needed to treat to benefit (NNTB) was 315, although with a perhaps more realistic control event rate of 2% it would be 127. The overall risk of pulmonary embolism appeared to be low, and the absolute benefit was small, so the apparent reduction in deep vein thrombosis may have little clinical relevance if there is not a correspondingly large reduction in pulmonary embolism. However, there may well have been under‐ascertainment of pulmonary embolism in all trials, given that data on pulmonary emboli were not sought systematically. In addition, deep vein thrombosis can lead to morbidity (such as post‐phlebitic leg and varicose ulcers), but data on these outcomes were not available from the included trials. Finally, it is possible that once anticoagulants are stopped, rebound thrombosis could occur, and deep vein thromboses may begin to develop. We were unable to exclude this possibility because no trials sought data on deep vein thrombosis systematically after the end of the treatment period. </p> <p>If anticoagulants result in no net increase or decrease in long‐term death or disability but do lead to a reduction in the numbers of deep vein thromboses and pulmonary emboli (albeit in immobile patients at higher risk), the benefit of fixed heparin regimens associated with low risk of bleeding (e.g. low fixed‐dose unfractionated heparin, low‐molecular weight heparin) may yet outweigh the increased risk of haemorrhage. A low deep vein thrombosis risk reduces the justification for unselective thromboprophylaxis with heparin. In <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a>, the frequency of fatal and non‐fatal symptomatic pulmonary embolism (perhaps a surrogate for the occurrence of deep vein thrombosis) was very similar among participants allocated to low‐dose subcutaneous heparin alone (0.8%) and aspirin alone (0.7%). Aspirin alone may therefore be an adequate antithrombotic agent to be used for routine deep vein thrombosis prophylaxis in some people with acute ischaemic stroke, as antiplatelet drugs, when used for prophylaxis of deep vein thrombosis and pulmonary embolism prophylaxis in other categories of high‐risk patients are of modest benefit (<a href="./references#CD000024-bbs2-0143" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ2002;324:71-86.">ATC 2002</a>). The <a href="./references#CD000024-bbs2-0146" title="CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet2013;382:516-24.">CLOTS‐3 2013</a> study demonstrated that for people with ischaemic and haemorrhagic stroke, intermittent pneumatic compression reduces the risk of deep vein thrombosis after stroke, without increased bleeding risk, and is effective in the presence and in the absence of background heparin therapy. </p> <p>Effects on deep vein thrombosis and pulmonary embolism presented in the present review indicate there might be a net benefit of low‐dose heparin regimens among patients who are at high risk of venous thromboembolism but at relatively low risk of intracranial or major extracranial bleeding. <a href="./references#CD000024-bbs2-0162" title="ShermanDG , AlbersGW , BladinC , FieschiC , GabbaiAA , KaseCS , et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL study): an open-label randomised comparison. Lancet2007;369:1347-55.">PREVAIL 2007</a> illustrates some of the difficulty involved in identifying subgroups who might have a favourable balance of risk and benefit. Although the risk of venous thromboembolism (VTE) (symptomatic plus asymptomatic) was significantly lower among participants allocated to enoxaparin, this study could not exclude a 69% increase in risk of death up to Day 14 and a 134% increase in risk of intracranial haemorrhage with enoxaparin. This is so because event rates for the more major clinical outcomes were low: among participants allocated unfractionated heparin, pulmonary embolism occurred in 1% and intracerebral haemorrhage in 1%. With such low event rates, conducting randomised trials large enough to reliably determine the balance of risk and benefit for these major clinical outcomes is challenging. In conclusion, data from the present review were insufficient to reliably identify a subgroup that might benefit from use of heparin for thromboprophylaxis. </p> </section> </section> <section id="CD000024-sec-0074"> <h3 class="title" id="CD000024-sec-0074">Overall completeness and applicability of evidence</h3> <p>This systematic review provides information about the use of anticoagulants for unselected people with ischaemic stroke, as well as limited information about various subgroups. Given that many of the trials were conducted more than 20 years ago, are these results still relevant to clinical practice in the 21st century? In the sense that they represent the totality of evidence comparing treatment with control, they remain relevant to current practice in many parts of the world and continue to be cited in stroke treatment guidelines. The pattern of background treatment has changed, with many patients now treated within organised stroke units (in the developed world at least). This might have an impact on the absolute risks and benefit of anticoagulation but is less likely to influence the estimates of relative effect, hence ‐ in our view ‐ the results remain relevant. Anticoagulants are also sometimes advocated for the treatment of acute carotid dissection and cerebral venous thrombosis. Separate Cochrane Reviews have been prepared for these topics (<a href="./references#CD000024-bbs2-0148" title="CoutinhoJ , deBruijnSFTM , deVeberG , StamJ . Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database of Systematic Reviews2011, Issue 8. Art. No: CD002005. [DOI: 10.1002/14651858.CD002005]">Coutinho 2011</a>; <a href="./references#CD000024-bbs2-0160" title="LyrerP , EngelterS . Antithrombotic drugs for carotid artery dissection. Cochrane Database of Systematic Reviews2010, Issue 10. Art. No: CD000255. [DOI: 10.1002/14651858.CD000255]">Lyrer 2010</a>). We were reluctant to pursue further subgroup analysis because it is hazardous to explore subgroup effects when there is no significant overall effect of an intervention on major outcomes, and we had access only to major outcomes. A more detailed assessment of the effects of anticoagulants for other categories of patients (e.g. patients treated within three hours, patients with large‐artery strokes, patients with carotid stenosis) would be possible with an individual patient data meta‐analysis. </p> <p>Stroke patients included in trials of anticoagulants to prevent deep vein thrombosis generally had quite severe strokes, and paralysis of one leg (with attendant high risk of deep vein thrombosis) was almost invariably present at randomisation. If, however, one accepts the estimate of treatment effect from these trials in the 1980s and 1990s, it is difficult to assess the extent to which it may be generalisable to clinical practice from 2000 onwards. In current practice, the risk of deep vein thrombosis may well be low because many patients are admitted to stroke units, receive aspirin, maintain good hydration, and are mobilised early. </p> <p>With that qualification in mind, the small quantities of (randomised) subgroup data evaluated here do not provide any evidence to support the routine use of anticoagulants in stroke patients of any specific category. </p> </section> <section id="CD000024-sec-0075"> <h3 class="title" id="CD000024-sec-0075">Quality of the evidence</h3> <p>The bulk of the evidence in this review comes from trials with adequate allocation concealment, which is a strength. However, <a href="./references#CD000024-bbs2-0012" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. Journal of Neurology Neurosurgery and Psychiatry1996;60:371-6. SaxenaR , LewisS , BergeE , SandercockP , KoudstaalP , for the International Stroke Trial Collaborative Group. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke2001;32:2333-7. ">IST 1997</a> ‐ by far the largest trial ‐ was unblinded ‐ which may well have led to ascertainment bias, especially for early outcomes. The final outcome, however, was assessed at a time when patients could not accurately recall their treatment allocation, so in all likelihood, assessment of the primary outcome probably was not materially biased. </p> </section> <section id="CD000024-sec-0076"> <h3 class="title" id="CD000024-sec-0076">Potential biases in the review process</h3> <p>This review is based on an analysis of tabular data, which limits the extent to which effects in subgroups can be explored. However, an individual patient data meta‐analysis has been performed. Included trials measured the primary outcome at differing times after randomisation, ranging from one to six months after randomisation, as we did not have access to individual patient level data to calculate person‐days or hazard ratios. In considering the impact of differing lengths of follow‐up on the primary outcome, a post‐hoc sensitivity analysis excluding the study with less than three months of follow‐up did not alter the overall estimate of effect nor reduce heterogeneity. </p> </section> <section id="CD000024-sec-0077"> <h3 class="title" id="CD000024-sec-0077">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD000024-bbs2-0158" title="LederleFA , ZyllaD , MacDonaldR , WiltT . Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine2011;155:602-15.">Lederle 2011</a> is a systematic review of venous thromboembolism prophylaxis in hospitalised medical patients and those with stroke, and review authors concluded, "Heparin prophylaxis had no significant effect on mortality, may have reduced PE (pulmonary embolism) in medical patients and all patients combined, and led to more bleeding and major bleeding events, thus resulting in little or no net benefit. No differences in benefits or harms were found according to type of heparin used." Similarly, there was no clear difference in effects between people with stroke and with other non‐surgical causes for hospital admission. A number of guideline statements have since been developed; the most recent American Stroke Association Guidelines include two specific recommendations that are supported by the evidence provided in this systematic review (<a href="./references#CD000024-bbs2-0140" title="WilliamP , AlejandroAR , TeriA , OpeoluMA , NicholasCB , KyraB , et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke2019;50:e344-e418. [DOI: https://doi.org/10.1161/STR.0000000000000211]">AHA Guidelines 2019</a>). These are as follows. </p> <p> <ul id="CD000024-list-0014"> <li> <p>Urgent anticoagulation, with the goal of preventing early recurrent stroke, halting neurological worsening, or improving outcomes after acute ischaemic stroke, is not recommended for treatment of patients with acute ischaemic stroke. </p> </li> <li> <p>At present, the usefulness of argatroban or other thrombin inhibitors for treatment of patients with acute ischaemic stroke is not well established. </p> </li> </ul> </p> <p>An individual patient data meta‐analysis of the large trials of heparin in acute ischaemic stroke was able to explore subgroup effects in greater detail, with the aim of identifying the subgroup of patients most likely to derive net benefit from heparin. However, the review authors concluded, "There was no evidence that patients with ischaemic stroke who were at higher risk of thrombotic events or lower risk of haemorrhagic events benefited from heparins. We were, therefore, unable to define a targeted approach to select the patients who would benefit from treatment with early anticoagulant therapy" (<a href="./references#CD000024-bbs2-0168" title="WhiteleyW , AdamsHP , BathPMW , BergeE , SandsetPM , DennisM , et al. Targeted use of heparin, heparinoids, or low-molecular weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurology2013;12:539-45.">Whiteley 2013</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000024-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for 2020 update." data-id="CD000024-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram for 2020 update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD000024-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-FIG-03" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD000024-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD000024-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-FIG-05" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD000024-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-FIG-06" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD000024-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 1: Dead or dependent at end of follow‐up (if &gt; 1 month)" data-id="CD000024-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 1: Dead or dependent at end of follow‐up (if &gt; 1 month) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 2: Death from all causes during treatment period" data-id="CD000024-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 2: Death from all causes during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 3: Death from all causes at final follow‐up (if &gt; 1 month)" data-id="CD000024-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 3: Death from all causes at final follow‐up (if &gt; 1 month) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 4: Deep vein thrombosis during treatment period" data-id="CD000024-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 4: Deep vein thrombosis during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 5: Recurrent ischaemic or unknown stroke during treatment period" data-id="CD000024-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 5: Recurrent ischaemic or unknown stroke during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 6: Symptomatic intracranial haemorrhage during treatment period" data-id="CD000024-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 6: Symptomatic intracranial haemorrhage during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 7: Any recurrent stroke or symptomatic intracranial haemorrhage during treatment period or follow‐up (&gt; 1 month)" data-id="CD000024-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 7: Any recurrent stroke or symptomatic intracranial haemorrhage during treatment period or follow‐up (&gt; 1 month) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 8: Symptomatic pulmonary embolism during treatment period" data-id="CD000024-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 8: Symptomatic pulmonary embolism during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 9: Major extracranial haemorrhage during treatment period" data-id="CD000024-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 9: Major extracranial haemorrhage during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 10: Subgroup analysis by type of anticoagulant agent used: effect on death or dependency" data-id="CD000024-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 10: Subgroup analysis by type of anticoagulant agent used: effect on death or dependency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 11: Subgroup analysis by anticoagulant dose: effect on death or dependency" data-id="CD000024-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 11: Subgroup analysis by anticoagulant dose: effect on death or dependency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 12: Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) in trials with adequate concealment of treatment allocation" data-id="CD000024-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 12: Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) in trials with adequate concealment of treatment allocation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 13: Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) for patients within 48 hours of stroke onset" data-id="CD000024-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 13: Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) for patients within 48 hours of stroke onset </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 14: Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) excluding IST3 trial" data-id="CD000024-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 14: Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) excluding IST3 trial </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 15: Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) excluding trial with assessment of primary outcome after only 1 month" data-id="CD000024-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 15: Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) excluding trial with assessment of primary outcome after only 1 month </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 16: Sensitivity analysis: deep vein thrombosis during treatment period restricted to trials where concealment of allocation was secure" data-id="CD000024-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 16: Sensitivity analysis: deep vein thrombosis during treatment period restricted to trials where concealment of allocation was secure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000024-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/urn:x-wiley:14651858:media:CD000024:CD000024-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 17: Sensitivity analysis: deep vein thrombosis during treatment period restricted to trials where radiographic assessment was blinded" data-id="CD000024-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_t/tCD000024-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Anticoagulant vs control in acute presumed ischaemic stroke, Outcome 17: Sensitivity analysis: deep vein thrombosis during treatment period restricted to trials where radiographic assessment was blinded </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/media/CDSR/CD000024/image_n/nCD000024-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000024-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Anticoagulant compared to control in acute presumed ischaemic stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anticoagulant compared to control in acute presumed ischaemic stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> acute presumed ischaemic stroke<br/><b>Setting:</b> hospital<br/><b>Intervention:</b> anticoagulant<br/><b>Comparison:</b> control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with anticoagulant</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dead or dependent at end of follow‐up (if &gt; 1 month)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>598 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>593 per 1000</b><br/>(578 to 605) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.98</b><br/>(0.92 to 1.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22428<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death from all causes during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b><br/>(78 to 93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.99</b><br/>(0.90 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22602<br/>(22 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 3 studies included in this analysis had low risk in each domain; only 2 out of 22 studies enrolled more than 500 patients, clearly underpowered </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deep vein thrombosis during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b><br/>(107 to 188) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.21</b><br/>(0.15 to 0.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>916<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies included in this analysis had low risk in each domain; all the studies were too underpowered to draw a firm conclusion; publication bias has been detected </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recurrent ischaemic or unknown stroke during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/>(24 to 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.75</b><br/>(0.65 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21665<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 2 studies included in this analysis had low risk in each domain</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic intracranial haemorrhage during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b><br/>(9 to 16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.47</b><br/>(1.90 to 3.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23221<br/>(21 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Publication bias has been detected</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic pulmonary embolism during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b><br/>(4 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.60</b><br/>(0.44 to 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22544<br/>(14 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major extracranial haemorrhage during treatment period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(9 to 15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.99</b><br/>(2.24 to 3.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22255<br/>(18 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Publication bias has been detected</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423948318800395805" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423948318800395805</a>. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Anticoagulant compared to control in acute presumed ischaemic stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/full#CD000024-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000024-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anticoagulant vs control in acute presumed ischaemic stroke</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Dead or dependent at end of follow‐up (if &gt; 1 month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Death from all causes during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Death from all causes at final follow‐up (if &gt; 1 month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.98, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Deep vein thrombosis during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.15, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Recurrent ischaemic or unknown stroke during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.65, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Symptomatic intracranial haemorrhage during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.47 [1.90, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Any recurrent stroke or symptomatic intracranial haemorrhage during treatment period or follow‐up (&gt; 1 month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Symptomatic pulmonary embolism during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.44, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Major extracranial haemorrhage during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.99 [2.24, 3.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Subgroup analysis by type of anticoagulant agent used: effect on death or dependency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22428</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Unfractionated heparin (subcutaneous) versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.94, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Low‐molecular‐weight heparin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.59, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 Heparinoid (subcutaneous) versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.29, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.4 Heparinoid (intravenous) versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.69, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.5 Direct thrombin inhibitor versus control (intravenous)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.55, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Subgroup analysis by anticoagulant dose: effect on death or dependency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Adjusted full‐dose intravenous anticoagulant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.70, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Medium fixed‐dose anticoagulant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Low fixed‐dose anticoagulant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) in trials with adequate concealment of treatment allocation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) for patients within 48 hours of stroke onset <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.89, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) excluding IST3 trial <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.69, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Sensitivity analysis: dead or dependent at end of follow‐up (if &gt; 1 month) excluding trial with assessment of primary outcome after only 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Sensitivity analysis: deep vein thrombosis during treatment period restricted to trials where concealment of allocation was secure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.16, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Sensitivity analysis: deep vein thrombosis during treatment period restricted to trials where radiographic assessment was blinded <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.27, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anticoagulant vs control in acute presumed ischaemic stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000024.pub5/references#CD000024-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000024.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000024-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000024-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000024-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD000024-note-0006">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD000024-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD000024-note-0007">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD000024-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD000024-note-0004">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000024\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000024\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000024\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000024\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000024\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000024.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000024.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000024.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000024.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000024.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715825671"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000024.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715825675"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000024.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d908e5fbbf55f',t:'MTc0MDcxNTgyNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 